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ABSTRACT OF DISSERTATION

PROTECTION AGAINST ENDOTHELIAL INFLAMMATION BY
GREEN TEA FLAVONOIDS

Endothelial inflammation is a pivotal early event in the development of
atherosclerosis. Long term exposure to cardiovascular risk factors will ultimately exhaust
those protective anti-inflammatory factors such as the heme oxygenase (HO) system.
The HO system plays a critical role in cellular and tissue self-defense against oxidative
stress and inflammation. Caveolae are membrane domains and are particularly abundant
in endothelial cells, where they are believed to play a major role in the regulation of
endothelial vesicular trafficking as well as the uptake of lipids and related lipophilic
compounds, possibly including bioactive food components such as flavonoids. Research
in this dissertation addresses the role of HO-1 and caveolae on dietary flavonoid
epigallocatechin gallate (EGCG) mediated protection against pro-inflammatory cytokine
tumor necrosis factor-α (TNF-α) and linoleic acid-induced activation of endothelial cells.
The data support the hypothesis that EGCG protects against TNF--induced monocyte
recruitment and adhesion partially through the induction of HO-1 and bilirubin. The
observed anti-inflammatory effects of EGCG are mimicked by the HO-1 inducer cobalt
protoporphyrin (CoPP) and abolished by HO-1 gene silencing. Nrf2 is the major
transcription factor of phase II antioxidant enzymes including HO-1. Results clearly show
that EGCG-induced HO-1 expression and subsequent bilirubin productions are dependent
on functional Nrf2. EGCG also can down-regulate the base-line level of caveolin-1.
Furthermore, silencing of the caveolin-1 gene can markedly down-regulate linoleic acidinduced COX-2 and MCP-1, indicating that caveolae may be a critical platform
regulating inflammatory signaling pathways. Similar to EGCG treatment, silencing of
caveolin-1 can also result in the activation of Nrf2, up-regulation of HO-1 and bilirubin.
This may be one of the mechanisms to explain the protection effect of caveolin-1 gene
silencing against endothelial inflammation. Moreover, EGCG rapidly accumulates in
caveolae, which is associated with caveolin-1 displacement from the plasma membrane
towards the cytosol. Caveolin-1 gene silencing can significantly reduce the uptake of
EGCG in endothelial cells within 30 min. These data suggest that caveolae may play a
role in the uptake and transport of EGCG in endothelial cells. These studies provide a

novel target through which EGCG functions to protect against inflammatory diseases
such as atherosclerosis.

KEYWORDS: epigallocatechin gallate (EGCG), heme oxygenase-1 (HO-1), caveolae,
linoleic acid, endothelial cells
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Chapter One: Introduction
Green tea (Camellia sinensis) catechins and vascular function
Polyphenols characterized by aromatic rings bearing one or more hydroxyl
substitutions are secondary metabolites of a wide variety of plants, including fruits,
vegetables, and legumes. Polyphenols also are enriched in plant-derived beverages, such
as tea and wine [4, 5]. Polyphenols are divided into more than ten different classes
depending on their chemical structures. The most widely distributed plant phenolics are
flavonoids. Flavonoids are composed of two benzene rings, A-ring and B-ring, and joined
by a three-carbon chain to form a closed heterocyclic C-ring. According to the degree of
oxidation in the C‐ring, flavonoids are divided into six major groups: flavones
(e.g.,luteolin,

apigenin),

flavonols

(e.g.,myricetin,

quercetin), catechins (e.g.,epicatechin, gallocatechin),
flavanones
anthocyanidins

(e.g.,

naringenin,

(e.g.,cyanidin,

hesperidin),

pelargonidin),

and

isoflavones (e.g.,genistein, daidzein) [3]. So far, more
than 5000 different flavonoids have been reported.

Flavonoids

They provide much of the color and flavor to
vegetables and fruits. Numerous studies focus on flavonoids’ abilities to protect against
oxidative stress and inflammation in disease processes. There are only a few estimations
of the daily intake of dietary flavonoids available. It has been reported that the average
daily intake of flavonoids in the United States is between 1 to 1.1g/day [6]. Higher intake
of flavonoids is associated with a reduced risk for coronary artery disease [7-10].
However, there are also some studies which have found no significant association after
elevated consumption of flavonoids [11]. Flavonoids have been of interest due to their
bioactive effects in vitro. Some of them are anti-inflammatory, anti-proliferative, and
anti-estrogenic agents; others are enzymatic activity modulators [5].
Tea is one of the most popular beverages in the world. Green tea (Camellia
sinensis) originates from Asia. It differs from black tea by the minimal fermentation of
tea leaves during production. Green tea is rich in polyphenols, about 80% of which are
catechins. They are epicatechin (EC), epigallocatechin (EGC), epicatechin-3-gallate
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(ECG), and epigallocatechin-3-gallate (EGCG). The most beneficial effects of green tea
are attributed to catechins. Flavonoids account for up to 30% of the dry weight of green
tea. EGCG is the most abundant and most bioactive catechin in green tea. A cup of green
tea contains 20-150 mg EGCG [12]. Green tea catechins are absorbed intestinally, with
peak absorption occurring at 1.5-2.5 h after consumption. The bioavailability of catechins
is low because of the poor absorption, and rapid metabolism. Only 2% of consumed
catechins appear in the plasma [13]. However, the biological activities of some green tea
catechin metabolites have been shown to have similar or even higher activity than the
parent compounds [14, 15].
Epidemiological studies have provided a clear link between the consumption of
green tea and the prevention of cardiovascular diseases. Imai showed that increased green
tea consumption can reduce total cholesterol, triacylglyceride and atherogenic index [16].
A recent study of 76,979 Japanese adults found that green tea consumption can decrease
death from cardiovascular disease [17] . There are only a few chronic human intervention
studies in the area of green tea and vascular function. Recently, Widlansky et al. [18]
specifically investigated the effects of isolated EGCG. They found that vascular function
was significantly increased after acute but not chronic supplementation. Conversely, Kim
et al. [19] found a significant improvement in flow-mediated dilation (FMD) –assessed
vascular reactivity after 14 d consumption of green tea. Similar conclusions were also
found by Tinahones et al. [20]. Lee et al. [21] conducted a study that showed a
significant reduction in soluble P-selectin and oxidized LDL after the consumption of 600
ml green tea for 28 d in 20 smokers. Numerous animal and cell-culture models also
indicate that green tea catechins have a positive effect on endothelial and overall vascular
functions.
In recent years, the mechanisms underlying the impact of green tea catechins on
vascular function have been the focus of much research. A number of plausible molecular
mechanisms have been proposed. A report by Nanjo et al. [22] suggested that EGCG is
the most effective catechin for free radical scavenging. Paquay et al. [23] showed that
EGCG could scavenge peroxynitrite, which can proceed to oxidize LDL or up-regulate
pro-inflammatory cytokines and adhesion molecules. Similarly, EGCG inhibited the
cytokine induction of VCAM-1 in HUVEC [24]. Pretreatment of human aortic
2

endothelial cells with catechin metabolites extracted from the plasma of catechin treated
rats significantly inhibited monocyte adhesion [25], suggesting that the metabolites of
catechins also have strong anti-inflammatory properties. The inhibition of endothelial
exocytosis and P-selectin cell-surface expression by EGCG has also been reported [26].
Moreover, catechins may down-regulate NADPH oxidase activity, reducing the
production of superoxide, and protecting NO from peroxynitrite formation [27].
Mizugaki et al. [28] reported that prostacyclin (PGI2), a potent vasodilator, was dosedependently induced by the addition of EGCG in cultured bovine endothelial cells.
Moreover, EGCG reduced the level of asymmetric dimethylarginine (ADMA), which
plays a crucial role in endothelial dysfunction and coronary artery disease [29]. ActisGoretta et al. [30] demonstrated that green tea can significantly inhibit the activity of
angiotensin-converting enzyme (ACE), which is an important mediator in blood pressure
regulation.
Endothelial cell dysfunction, inflammation and atherosclerosis
Cardiovascular disease (CVD) is America's leading killer for both men and
women among all racial groups. Almost 1 million Americans die of CVD each year.
CVD is responsible for more than 30 percent of all deaths in the United States. Almost 75%
of all deaths from cardiovascular disease are due to myocardial infarction or stroke
caused by atherosclerosis. Atherosclerosis is a chronic inflammatory disease developing
in the arterial wall in response to various injurious stimuli and resulting in excessive
inflammatory reactions. Endothelial cells (ECs) are involved in all stages of
atherogenesis and their dysfunction initiates plaques formation [31, 32].
The endothelium separates the plasma and the underlying tissue, and its
constitutive properties are involved in a large array of functions. Under physiological
conditions, ECs regulate vasoconstriction and vasodilation, and hence the control of
blood pressure. The endothelium acts as a selective barrier between the vessel lumen and
underlying tissue, monitoring the transport of materials and plasma molecules into and
out of the bloodstream. Excessive increases in permeability of the endothelial layer may
lead to tissue edema. In addition, ECs play a crucial role in regulating cholesterol and
lipid homeostasis, signal transduction, inflammation and haemostasis [33, 34]. Under
3

pathological conditions, endothelial dysfunction is a biomarker for vascular diseases and
is often regarded as a key early event in the development of atherosclerotic plaques.
Impaired endothelial function is often seen in patients with coronary artery disease,
diabetes mellitus, hypertension, and hypercholesterolemia.
A pivotal early event in the development of atherosclerosis is the activation of ECs
by persistent dyslipidemia generated ROS, which has been increasingly recognized as a
common denominator that induces most cardiovascular diseases. Hydrogen peroxide and
superoxide anions are two of the most important biological ROS in cardiovascular
systems. Excessive ROS production stimulates various endothelial events, including
induction of inflammatory gene, monocyte adhesion, platelet aggregation, and impaired
endothelium-dependent relaxation [35]. ROS production is positively regulated by many
cytokines whose expressions are induced in activated ECs. These cytokines include
tumor necrosis factor- (TNF-), interleukins (IL), angiotensin II, vascular endothelial
growth factor and CAMs: intercellular adhesion molecule-1 (ICAM), vascular cell
adhesion molecule-1 (VCAM-1), E and P selectin and chemokines, such as the monocyte
chemoattractant protein-1 (MCP-1). Lipid infusion also stimulates the production of ROS
and inflammation [31]. NF-B is an inducible transcription factor which is activated by
several cytokines and growth factors found in atherosclerotic lesions, such as MCP-1,
TNF-andIL-1Evidence suggests that oxidative stress stimulates the translocation of
NF-B from the cytoplasm to the nucleus [36]. AP-1 is another important transcription
factor influenced by the cellular redox state, and induced by H2O2, LDL, and oxLDL, to
regulate vascular inflammatory genes, such as MCP-1and ICAM-1 [37].
Nitric oxide regulates vascular tone and also has anti-atherogenic effects on EC
and platelets [38]. NO bioactivity is significantly decreased in atherosclerosis due to
diminished eNOS expression and activity, eNOS uncoupling, and impaired NO-regulated
cell signaling [39]. Endothelial regulated vascular tone is dependent on the synthesis and
release of vasodilators, such as NO, prostacyclin and EDHF, of vasoconstrictors, such as
endothelin-1(ET-1), angiotensin II, and prostanoids. Increased plasma levels of remnantlike lipoprotein particles (PLp), which are highly atherogenic, may impair endothelial
functions through eNOS [40]. Endothelial CD36 is a scavenger receptor (SR) that binds
to oxLDL, trombospondin, and long-chain fatty acids. LOX-1 which mediates the action
4

of oxLDL in the vascular wall is also detected in EC in early atherosclerosis, and it is
induced by ROS, ET-1, TNF-and inflammatory molecules [41].
In the early stage of atherosclerosis, modified lipoproteins accumulate in the
intima, the endothelial cell lining plaques take up modified lipoproteins, which are either
degraded or exocytosed into the lumen. Also, EC-SR non-regulated uptake of the
modified lipoproteins results in the accumulation of some large lipid droplets within the
EC [31, 42]. Later, local inflammatory regulators, cytokines, ROS and oxLDL induce EC
synthesis of MMP, and finally trigger EC apoptosis [43]. In more advanced stages of
atherosclerosis, formation of fibrous plaques and lesions will ultimately lead to an acute
clinical event by plaque rapture and thrombosis [44, 45].
Overall, the inflammatory reaction in endothelial cells is regulated by complex
interactions. Long time exposure to cardiovascular risk factors will ultimately exhaust
those protective anti-inflammatory factors in EC. Since the initial stage of atherosclerosis
is the critical time point when nutrition (e.g. flavonoids) modulation could have the most
efficient effects, the research in the current dissertation focuses on the early events of
atherosclerosis, including the role of caveolae and heme oxygenase-1 (HO-1) on dietary
flavonoid EGCG-mediated protection against pro-inflammatory cytokine tumor necrosis
factor (TNF)-α or linoleic acid-induced activation of endothelial cells.
Caveolae and atherosclerosis
Caveolae are 50-100 nm omega-shaped cell membrane invaginations present in
almost all cell types in cardiovascular systems [46]. They have been widely studied since
their initial description by electron microscopy in 1950. Caveolae are a subcategory of
lipid rafts and are enriched in structural proteins called caveolins. Three caveolin
homologues exist, caveolin-1, -2, and -3, with molecular weights of about 24 kDa.
Caveolin-1 and -3 are necessary for the formation of caveolae structure, while caveolin-2
is dispensable. Endothelial cells, adipocytes, pneumocytes, and fibroblasts have the
highest levels of caveolin-1 and -2 [47, 48], while caveolin-3 expression is restricted to
smooth and striated muscle cells [49]. Since caveolae are highly enriched in endothelial
cells, cavolin-1-deficient mice showed several defects that correlated with endothelial
cells [50].

Studies show that caveolae play an important role in the regulation of
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endothelial cell function. The most frequently studied area focused on the ability of
caveolae to mediate endothelial nitric oxide synthase (eNOS) and their role in the
regulation of angiogenesis. Researchers found that caveolin-1-deficient mice displayed
increased eNOS activity, pulmonary dysfunction, and cardiomyopathy [51-53]. The fatty
acid composition of caveolae in endothelial cells has been documented by Gafencu et al.
[54]. They found that palmitic acid, palmitoleic, stearic acid, and oleic acid are most
prevalent and compose 80% of total fatty acids; and linoleic acid is about 8 to 10% of
total fatty acids. Ma et al. [55] found that omega-3 fatty acids altered the function of
proteins in caveolae by reducing both caveolin-1 and cholesterol in mice colons. Li et al.
[56] reported that eicosapentaenoic acid (EPA) induced caveolin-1 translocation from
caveolae towards cytosol in endothelial cells.
One of the aspects of caveolae that makes them an interesting research subject is
the fact that they are believed to harbor a subset of important signal transduction
molecules and receptors. Several G proteins and G protein-coupled receptors (GPCRs)
[57], tyrosine kinase-coupled receptors [58], such as epidermal growth factor receptors,
vascular endothelial growth factor receptors and transforming growth factor receptors,
have been reported to reside in caveolae. eNOS is another important caveolae-associated
signaling enzyme. Caveolin-1 inhibits eNOS activity [59]. Increased eNOS activity has
been observed by several groups in caveolin-1 deficient mice. Moreover, increased
plasma levels of NO oxidation products, nitrite and nitrate were documented [52, 60].
PKC is also dynamically associated with caveolae [61, 62]. The scaffolding domain of
caveolae which is responsible for molecular interactions inhibit PKC activity [63] and
vasoconstriction [64]. In some arteries of caveolin-1 deficient mice, PKC-regulated
vasoconstriction is increased [65]. Although caveolae play a critical role in several
signaling pathways, surprisingly, the mice lacking caveolae are both viable and fertile
[52]. However, there are still some phenotypes which involve heart, lungs and blood
vessel change, e.g., increased thickness of the left ventricular wall [51], increased fibrosis
in many organs including the heart [66], and pulmonary arterial hypertension [67].
In endothelial cells, another important function of caveolae is their ability to
transfer molecules from the lumen of blood vessels to the sub-endothelial space, a
process called transcytosis. Three different pathways exist: receptor-mediated
6

transcytosis, fluid-phase transcytosis, and paracellular transfer. Caveolae are involved in
the first two pathways. For example, caveolae can transport albumin [68], insulin [69],
low-density lipoproteins (LDL), modified LDL [68, 70], and chemokines [71]. These
transcytosis systems play a critical role in protection and regulation of homeostasis, and
specific and targeted delivery of molecules. As is well known, the transcytosis of LDL
across endothelial cells is an important event in the development of atherosclerosis.
Although it has been studied for more than three decades, the specificity of the pathway
is still not very clear as contradictory results showed presence or absence of a specific
receptor of LDL [72]. Some receptors, such as CD36, SR-B1 and the LDL receptor may
be the candidate receptors. Since the accumulation of modified LDL in the subendothelial space is the initial step in the development of atherosclerosis, the elimination
of this transcytosis would therefore be associated with reduced atherosclerotic lesions.
Studies have shown that the absence of caveolae in apolipoprotein-E/caveolin-1 double
knockout mice reduced fatty streak lesion formation by about 70% compared with apo-Edeficient mice [73]. Since the transcytosis process seriously affects endothelial
permeability, many studies have focused on the pathways regulated by caveolin-1
involved in the regulation of endothelial permeability. It has been shown that eNOS and
NF-B are involved in these signaling pathways. Increased activity of eNOS in caveolin1 deficient mice displayed increased vascular permeability, shown by increased albumin
transportation [73].
Besides transcytosis, caveolae also play an important role in endocytosis. Unlike
clathrin-mediated endocytosis, internalization through caveolae involves complex
signaling [74]. Caveolin-1, the major scaffolding protein constituent of caveolae,
participates in vesicular trafficking and signal transduction. And caveolin-1 can cycle
between the plasma membrane and several intracellular compartments [75]. Caveolae are
particularly abundant in endothelial cells, where they are believed to play a major role in
the regulation of endothelial vesicular trafficking as well as the uptake of lipids and
related lipophilic compounds possibly including bioactive food components such as
flavonoids by means of endocytosis [76, 77].
Little is known about the involvement of caveolae in gene regulation by
bioactive compounds. Genistein has been shown to decrease the expression of caveolin-1
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in ovariectomized rat hearts [78]. Furthermore, our lab found that quercetin could
decrease caveolin-1 protein expression in endothelial cells [79]. All these results suggest
that these bioactive compounds can modulate the function of caveolae. Recently, it has
been reported that the laminin receptor which resides in lipid rafts as a cell surface
receptor could form laminin receptor-EGCG complex and link EGCG action to MAPK
pathways [80, 81]. These findings suggest that lipid rafts may be associated with the
function of EGCG. Caveolae, a subcategory of lipid rafts, may also provide an active
platform for optimal tuning of signaling responses. The dynamic regulation of signaling
transduction through recruitment of EGCG targeting caveolae may result in
reprogramming of cellular responses.
Heme oxygenase-1, nuclear factor-E2-related factor 2 (Nrf2) and cardiovascular
diseases
Heme oxygease-1 (HO-1) is an inducible isoform of the rate-controlling enzyme
degrading heme to carbon monoxide (CO), ferrous (Fe2+) and biliverdin, the latter being
subsequently converted into bilirubin. Heme is the prosthetic group of several enzymes
which play critical roles in the regulation of endothelial function. These enzymes include
nitric oxide synthase (NOS), cytochrome P450, monooxygenase, cyclooxygenase (COX)
and catalase [82]. Excess heme catalyzes the formation of reactive oxygen species,
which cause endothelial dysfunction. Therefore, the HO system may be recognized as a
protector of endothelial cell integrity. It has been reported that HO systems have three
isoenzymes HO-1, -2, and -3. HO-2 is the constitutive isoform. HO-3 is only expressed in
rats. HO-1 is the only inducible isoform which can be up-regulated by a wide spectrum of
inducers, including endotoxin, heavy metals, oxidants, and hypoxia and pharmaceutical
agents, such as aspirin, statins, probucol, losatan and resveratrol [1]. These products have
both physiological and pathological functions. CO is not an antioxidant, but it could
induce antioxidant genes. CO scavenges superoxide [83], and increases glutathione level
[84]. Furthermore, CO induces cGMP level, leading to vasorelaxation [85]. Bilirubin has
strong anti-oxidant properties which have been shown to scavenge reactive oxygen
species, inhibit NADPH oxidase activity [86], preserve endothelial integrity, in part by
increasing the bioavailability of NO required for endothelial integrity [87]. Bilirubin also
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inhibits oxidation of low density lipoprotein [88]. Therefore, HO-1 derived bilirubin
plays an important role in cellular and tissue self-defense against oxidative stress. Higher
serum bilirubin levels are associated with a decreased risk for coronary artery disease
[89]. Induction of CO and bilirubin has shown promise in protecting against oxidative
stress, whereas HO-1 deficient mice showed accelerated atherosclerotic lesion formation,
vein-graft disease and elevated blood pressure [90]. Moreover, it has been shown by
several laboratories that HO-1 up-regulation is cytoprotective in atherosclerosis [91],
diabetes [83], lung injury [92], and occlusive vascular disease [93].
HO-1 is highly expressed in the endothelium and foam cells of atherosclerotic
lesions [94]. In vascular endothelial cells, smooth muscle cells, and macrophages, HO-1
can be induced by oxLDL, a major determinant in the pathogenesis of atherosclerosis
[95]. HO-1 expression and activity is high throughout the development of atherosclerosis,
from an early fatty streak to an advanced complex atherosclerotic lesion in human aortic
endothelial cells and smooth muscle cells. It has been reported in LDL receptor deficient
mice or Watanabe heritable hyperlipidemic rabbits that the induction of HO-1 could
reduce atherosclerotic lesion size [96, 97]. Moreover, HO-1 knockout mice with an
apolipoprotein E deficient background showed accelerated atherosclerotic lesions
compared with apolipoprotein E deficient mice [98]. Induction of HO-1 by
pharmaceutical agents or adenovirus-mediated gene transfer reduces atherosclerosis in
murine models [91]. Endothelial dysfunction is a well established response to
cardiovascular risk factors, and precedes the development of atherosclerosis. Endothelial
activation caused by oxLDL and TNF-is critical in the development of atherosclerosis.
HO-1 induction in endothelial cells attenuates inflammatory mediator production, and
reverses oxLDL and TNF--impaired-vasodilatory responses [99].

CO inhibits the

lipopolysaccharide-induced expression of pro-inflammatory cytokines, such as IL-1,
TNF-, and increases the expression of anti-inflammatory cytokine IL-10 in both
endothelial and macrophages [100]. CO induces sGC and cGMP levels, which regulate
blood pressure and vascular contractility [101].
The expression of HO-1 may be regulated by NF-E2-related factor 2 (Nrf2), a
leucine zipper transcription factor. Nrf2 plays an essential role in the up-regulation of
phase II anti-oxidant genes, including HO-1 [102]. Its activity is in part regulated by an
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Nrf2 inhibitory protein called Kelch-like ECH-associated protein 1 (Keap1). Keap1
suppresses the transcriptional activity of Nrf2 by specifically binding to its evolutionarily
conserved amino-terminal in the cytoplasm. When electrophiles or other reactive species
activate cells, Keap1 dissociates with Nrf2, releases Nrf2 and allows this transcription
factor to traverse from the cytoplasm into the nucleus. Once migrated to the nucleus, Nrf2
forms heterodimers with small Maf proteins and subsequently binds to the cis-acting
antioxidant response element (ARE). This leads to the transcriptional activation of a
number of genes that encode for the phase II detoxifying or antioxidant enzymes, such as
NQO1, GST, GCL, and HO-1 [103].
It has been reported that the induction of endogenous anti-oxidative enzymes by
tea flavonoids contributes to their anti-oxidative effect. Wu et al. found that EGCG
protection against oxidative stress by the induction of HO-1 in human endothelial cells is
PI3K/Akt-dependent [104]. The aim of this dissertation project was to understand
whether the induction of HO-1 by EGCG in endothelial cells correlated with its
protective effects and whether direct inhibition of HO-1 will diminish EGCG-mediated
protection against TNF-induced endothelial activation.
TNF-α induces endothelial dysfunction
TNF-α, one of the most potent pro-inflammatory cytokines [105], is highly
expressed throughout the full spectrum of atherosclerotic development [106]. TNF-is a
critical player in inflammation through stimulating the expression of adhesion molecules
on endothelium and decreasing endothelial NO generation thereby inducing endothelial
dysfunction [107]. Accumulating evidence suggests that TNF-is important in the
disruption of macrovascular and microvascular circulation by modulating advanced
glycation end-products (AGEs), receptor for AGEs (RAGE), lectin-like oxidized lowdensity lipoprotein receptor-1 (LOX-1) and NF-B regulated signaling pathways [108].
TNF-stimulates superoxide production in endothelial cells through NADPH oxidase
[109], XO [110], NOS [111] and other pathways. The production of ROS stimulates a
cytokine cascade which induces the expression of TNF-TNF-also affects and
mediates lipid metabolism. TNF-levels are associated with the concentration of very
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low density lipoprotein (VLDL), triacylglycerol, and cholesterol and negatively with high
density lipoprotein (HDL) in hyperlipidaemia patients [113]. In the current study,
endothelial cells were stimulated with TNF- to induce inflammation.
Linoleic acid induces endothelial inflammation
Linoleic acid (LA, 18:2n-6) is the primary essential fatty acid and represents the
basis of the omega-6 family. Linoleic acid is enriched in safflower oil, sunflower oil,
corn oil, peanut oil and cotton seed oils, accounting for more than half of the total fatty
acid in these oils [114]. Diets high in omega-6 fatty acids are associated with increased
inflammation and thus an increased risk for cardiovascular diseases. Linoleic acid, the
major omega-6 fatty acid in the American diet, is recognized to be pro-inflammatory and
pro-atherogenic since it favors oxidative modification of LDL cholesterol, and increases
platelet aggregation [115]. Although diets high in omega-6 fatty acids may decrease
serum cholesterol [116], it is not a good choice to replace saturated with unsaturated
omega-6 fatty acid because they are easily oxidized. High intake of linoleic acid–rich oils
or fats causes cellular oxidative stress and induces an inflammatory response [117],
which initiates the development of endothelial dysfunction and atherosclerosis. It has
been reported that linoleic acid induced oxidative stress, increased intracellular calcium
levels [118] , and diminished nitric oxide synthase activity [119] in cultured endothelial
cells. People demonstrated that linoleic acid could potentiate TNF-α–mediated
endothelial injury [120]. Our lab has reported that both the extracellular signal regulated
kinase (ERK1/2) and phosphoinositide-3 kinase/amino kinase terminal signaling
pathways contribute to the effect of linoleic acid on NF-κB-mediated endothelial cell
activation [121]. Linoleic acid is proatherogenic by inducing arterial smooth muscle cell
proliferation [122]. Moreover, linoleic acid derived from the hydrolysis of triglyceriderich lipoproteins caused endothelial injury [120]. The current hypothesis is that linoleic
acid-induced signaling pathways can be affected by bioactive food components such as
epigallocatechin-3-gallate (EGCG), and that these metabolic events are linked to
caveolae signaling.
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Hypothesis and significance of the current study
Previous studies have demonstrated that increasing levels of circulating cytokines
such as TNF-α can induce endothelial activation and promote an inflammatory response
[121, 123]. Epidemiological studies have provided a clear link between the consumption
of green tea and the prevention against cardiovascular diseases. A number of plausible
molecular mechanisms using the green tea extracts EGCG have been proposed. However,
the role of caveolae on the protection effects of EGCG against endothelial cell activation
has not been explored. It is possible that caveolae play a role in the uptake and transport
of EGCG, and that EGCG can alter the membrane lipid rafts (caveolae) environment,
therefore affecting the connected cell signaling transduction and gene expression. This
dissertation investigated the regulation of signaling pathways induced by bioactive
compounds within caveolae and linked to caveolae function and associated gene
inductions. Specifically, it was elucidated how dietary omega-6 fatty acid-induced
signaling pathways are regulated by bioactive food components such as EGCG and the
subsequent events linked to caveolae signaling.
This dissertation also describes the role of HO-1 in EGCG-mediated protection
against TNF--induced endothelial activation. The heme oxygenase system is an
important regulator of endothelial cell integrity and oxidative stress. HO-1 deficient mice
showed accelerated atherosclerotic lesion formation, vein-graft disease and elevated
blood pressure [90]. Moreover, HO-1 up-regulation is cytoprotective in atherosclerosis
[91]. Thus, a major objective of the current study was to explore the role of HO-1 on
mechanisms of EGCG-mediated protection of the vascular endothelium. The hypothesis
tested was that EGCG can exhibit anti-inflammatory properties partially via induction of
HO-1 and subsequent AP-1 signaling.
Induction of Nrf2-ARE signaling provides a cellular self-defense against a variety
of electrophilic compounds, reactive toxicants and oxidant induced cell stress [124]. To
further explore the hypothesis that caveolae play a role in the uptake and transport of
EGCG and the association with the activation of Nrf2/HO-1 cellular self-defense system,
EGCG levels in caveolae-enriched fractions were quantified, and the effect of EGCG on
the activation of Nrf2 and HO-1 with or without functional caveolae was explored. It was
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hypothesized that EGCG can stimulate caveolin-1 displacement from lipid microdomains
towards the cytosol, thereby altering their functionality and subsequent downstream
signaling. These investigations may provide a novel target through which EGCG
functions to protect against inflammatory diseases such as atherosclerosis.
In summary, this dissertation describes and elucidates caveolae and HO-1
associated mechanisms of inflammatory diseases and protection by bioactive food
components with antioxidant and anti-inflammatory properties such as the green tea
catechin EGCG.
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Figure 1-1 Classification of flavonoids. Adapted from Ross et al [3]
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Figure 1-2 The heme oxygenase (HO) system, including the metabolism of heme and
effects of HO on its final products. Adapted from Peterson et al [1]
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Figure 1-3 Caveolae and lipid rafts. Adapted from Galbiati et al [2]
A) Electron micrograph of an endothelial cell showing caveolae
B) The biochemical composition of lipid rafts and caveolae

Copyright © Yuanyuan Zheng 2010
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Chapter Two: Role of caveolin-1 in EGCG-mediated protection against linoleic
acid-induced endothelial cell activation
This work has been published in the Journal of Nutritional Biochemistry (Zheng et al., J
Nutr Biochem 2009 Mar; 20 (3):202-9).

Synopsis
Flavonoids can protect against inflammatory diseases such as atherosclerosis by
decreasing vascular endothelial cell activation. Plasma microdomains called caveolae
may be critical in regulating endothelial activation. Caveolae are particularly abundant in
endothelial cells and play a major role in endothelial trafficking and the regulation of
signaling pathways associated with the pathology of vascular diseases. We hypothesize
that flavonoids can down-regulate endothelial inflammatory parameters by modulating
caveolae-regulated cell signaling. We focused on the role of caveolae and its major
protein, caveolin-1, in mechanisms of linoleic acid-induced endothelial cell activation
and protection by the catechin EGCG. Exposure to linoleic acid for 6 h induced both
caveolin-1 and COX-2 expression. Pretreatment with EGCG blocked fatty acid-induced
caveolin-1 and COX-2 expression in a time and concentration-dependent manner.
Similar results were observed with NF-κB DNA binding activity, which was also reduced
by caveolin-1 silencing. Exposure to linoleic acid rapidly increased phosphorylation of
several kinases, including p38 MAPK, ERK1/2, and Akt, with maximal induction at
about 10 min. Inhibitors of ERK1/2 and Akt down-regulated the linoleic acid-induced
increase in COX-2 protein, which also occurred after pretreatment with EGCG. Caveolin1 silencing blocked linoleic acid-induced phosphorylation of ERK1/2 and protein
expression of COX-2, suggesting that specific MAPK signaling is caveolae-dependent.
Our data provide evidence that caveolae may play a critical role in regulating vascular
endothelial cell activation and protection by flavonoids such as EGCG.
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Introduction
Endothelium locates between the plasma and the underlying tissue and its
constitutive properties are involved in a large array of functions. The lining of blood
vessels is protected by the endothelium, and dysfunction of endothelial cells is a critical
underlying cause of the initiation of cardiovascular diseases [123]. Under pathological
conditions, endothelial dysfunction is a biomarker for vascular diseases and is often
regarded as a key early event in the development of atherosclerotic plaques. In addition to
endothelial barrier dysfunction, another functional change leading to atherosclerosis is
the activation of the endothelium by pro-inflammatory mediators that regulate the
vascular entry of leukocytes. COX-2 is an inducible isoform of cyclooxygenase, which
converts arachidonic acid to prostaglandin. It plays a crucial role in inflammation. The
expression of COX-2 is low in endothelial cells, but it could be up-regulated by proinflammatory reagents [125]. Cyclooxygenase inhibitors can be applied to reduce
inflammation, to relieve from pain, or to prevent atherothrombotic complications in
cardiovascular diseases [126].
Hypertriglyceridemia is an independent risk factor of cardiovascular diseases such
as atherosclerosis [127, 128]. Dietary balance of long-chain fatty acids may influence
processes involving leukocyte-endothelium interactions [129]. Diets high in omega-6
fatty acids have been shown to increase the risk of cardiovascular diseases. Linoleic acid
belongs to omega-6 fatty acid family. It is abundant in many vegetable oils, especially
safflower and sunflower oils. High intake of linoleic acid-rich oils or fats will lead to an
increase in cellular oxidative stress, which has been implicated in most chronic diseases.
Even though diets high in omega-6 fatty acids may lead to a decrease in serum
cholesterol [116], replacing saturated with unsaturated omega-6 rich lipids may not be
desirable because of their ability to easily oxidize. Omega-6 fatty acids, and especially
linoleic acid can cause endothelial cell dysfunction as well as potentiate tumor necrosis
factor- (TNF-)-mediated endothelial injury [120]. Previous studies have shown that
linoleic acid potentiated TNF-α–mediated pro-inflammatory responses in endothelial
cells [130]. Linoleic acid may further be atherogenic by causing activation of nuclear
factor-kappa B (NF-κB) which in turn induces the expression of E-selectin and VCAM-1
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[120, 131]. We have recently demonstrated that both the extracellular signal regulated
kinase (ERK1/2) and phosphoinositide-3 kinase/ amino kinase terminal (PI3K/Akt)
signaling pathways can contribute to the effect of linoleic acid on NF-κB-dependent
transcription and endothelial cell activation [121].
Diets high in various nutrients and phytochemicals (e.g., flavonoids) are
associated with a reduced risk of chronic diseases, such as cardiovascular diseases and
cancer, by affecting molecular mechanisms involved in the initiation and progression of
these diseases [132, 133]. Polyphenols comprise a diverse group of compounds that are
secondary metabolites of plants, characterized by aromatic rings bearing one or more
hydroxyl substitutions [4]. Flavonoids are a kind of polyphenols which rich in fruits and
vegetables, soy food, legumes, tea and cocoa [134]. Flavonoids are composed of two
benzene ring, A-ring and B-ring, and joined by a three -carbon- chain to form a closed Cring [135]. Examples of flavonoids include flavonols (e.g., quercetin), isoflavones (e.g.,
genistein), flavonones (e.g., hesperetin), and flanan-3-ols (e.g., catechins). Flavonoids
are extensively studied for their antioxidant and anti-inflammatory abilities. However,
various studies have shown that flavonoids can be cardioprotective as antioxidants, but
also via antioxidant independent mechanisms [136]. Many of these bioactive food
components are lipophilic, suggesting they may have a possible interaction with
membrane domains or cellular lipid components such caveolae.
Caveolae have been recognized a specialized form of lipid raft [137]. But certain
structure proteins have been found to preferentially partition into lipid rafts or caveolae
but not both [138]. The localization caveolin proteins to caveolae distinguishes these
membrane domains from lipid rafts [139]. There are three gene family members of
caveolin: caveolin-1, -2, and -3. Cholesterol and glycosphingolipids are essential
components of caveolae. There is increasing evidence that caveolae play a critical role in
the pathology of atherosclerosis [140] and that the lack of the caveolin-1 gene may
provide protection against the development of atherosclerosis [141].

Caveolae are

particularly abundant in endothelial cells, where they are believed to play a major role in
the regulation of endothelial vesicular trafficking as well as the uptake of lipids and
related lipophilic compounds [76], possibly including bioactive food components such as
flavonoids. There is evidence that fatty acids can alter localization and function of
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caveolae-associated signaling proteins in mouse colonic mucosa [56]. Caveolins also
have been reported to co-localize with cyclooxygenase, suggesting that caveolins play a
role in regulating the function of this enzyme [142, 143]. Besides their role in cellular
uptake of lipophilic substances, caveolae house an array of cell signaling molecules, and
numerous genes involved in endothelial cell dysfunction and inflammation are associated
with caveolae [140].
There is few study focused on the role of caveolae in gene regulation by bioactive
compounds. Genistein has been shown to decrease the expression of caveolin-1 in
ovariectomized rat hearts [78]. Our laboratory recently found that co-treatment with
quercetin reduced PCB77 induced caveolin-1 protein expression [79]. Furthermore, the
internalization of caveolae can be suppressed by tyrosine kinase inhibitors such as
staurosporine [144]. Flavonoids have been described to inhibit these kinases [145, 146],
which suggests that these bioactive compounds can modulate the function of caveolae.
The current study focused on specific mechanisms involved in anti-inflammatory
properties of bioactive compounds like flavonoids within the vascular endothelium. We
hypothesized that caveolae may play a role in the regulation of signaling pathways
induced by linoleic acid and protection by bioactive compounds. Our data provide
evidence that linoleic acid-induced signaling pathways can be down-regulated by
bioactive food components such as epigallocatechin-3-gallate (EGCG) and that these
metabolic events are linked to caveolae signaling.
Materials and Methods
Materials

Epigallocatechin gallate (EGCG, >98% pure), was obtained from Cayman
Chemical (Ann Arbor, MI). Linoleic acid (>99% pure), was obtained from Nu-Chek
Prep (Elysian, MN). Anti-caveolin-1 was obtained from Affinity BioReagents (Golden,
MO). Anti-COX-2 and anti-p65 NF-B were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti-β-actin was purchased from Sigma (Saint Louis, MO). Inhibitors
LY294002, PD98059, and SB 203580 as well as antibodies used for immunobloting
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including anti-Akt, anti-phospho Akt, anti-ERK, anti-phospho ERK, anti-p38, antiphospho p38, and anti-rabbit Ig horseradish peroxidase linked were obtained from Cell
Signaling Technology (Danvers, MA).

Supplies and reagents for SDS-PAGE were

purchased from Bio-Rad (Hercules, CA).

Cell culture
EAhy 926 cells were a gift from Dr. C. S. Edgell (University of North Carolina).
The EAhy 926 line was derived by fusing human umbilical vein endothelial cells with the
permanent human cell line A549 [147]. The culture medium consisted of Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA), 10% fetal bovine serum
(FBS; Hyclone, Logan, UT), and antibiotics. Cell cultures were grown until confluent,
and then synchronized by maintaining in 1% serum for 16 h before treatment for various
times periods.

Experimental media contained 5% FBS and was supplemented with

EGCG for 12 h, and followed by linoleic acid at the final concentration of 90 µM, for 6 h.
Preparation of experimental media with linoleic acid was performed as described
previously [148]. It has been demonstrated [149] that the molar ratio of free fatty acid to
albumin is the main factor controlling free fatty acid availability to tissues. Plasma
albumin concentration is about 600 μM, and total free fatty acid is between180 and 2000
μM. In another word, the range of ratios of fatty acid to albumin is 0.3 to 4. In my study,
90 μM fatty acids were enriched in 5% media with which the albumin concentration is
about 60 μM, thus the ratio of free fatty acids to albumin is within physiological range.

Caveolin-1 siRNA and transfection
The caveolin-1 gene silencer was designed according to previously described
methods [150]. The caveolin-1 gene silencer was designed by Dharmacon (Lafayette
Colorado). The sequences of caveolin-1 gene silencer were 5'- CCAGAAGGGACA
CACAGUUdTdT-3' (sense), 5'- AACUGUGUGUCCCUUCUGGdTdT-3' (anti-sense).
The sequences of the control gene silencer were 5’-AAAGAGCGACUUUACACAC
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dTdT-3' (sense), 5’-GUGUGUAAAGUCGCUCUUUdTdT -3' (anti-sense). Cells were
transfected with control siRNA or caveolin-1 siRNA at a final concentration of 80 nM
using GeneSilencer (Genlantis, San Diego, CA) with Optimem I medium (Invitrogen,
Carlsbad, CA). Cells were incubated with transfection mixtures for 4 h and then replaced
with 10% serum medium. Cells were synchronized overnight after 48 h transfection, pretreated with EGCG for 12 h, and then treated with linoleic acid or vehicle.

Immunoblot analysis of caveolin-1, COX-2, phospho-Akt, ERK, and p38 MAPK
protein expression

Cells were treated with either vehicle (0.1% DMSO) or EGCG (0-40 µM)
followed by linoleic acid (90 µM) for immunoblot analysis of caveolin-1 and COX-2
protein activation. Treatment with DMSO (vehicle) alone for up to 48 h did not affect the
expression of both caveolin-1 and COX-2 (data not shown). To analyze the expression of
phospho-Akt, -ERK, and -p38, cells were treated Akt, ERK, and p38 inhibitors
(LY294002, PD98059, and SB 203580) for 1 h, followed by linoleic acid (90 µM, 10
min), or vehicle (0.1% DMSO). Cell protein was extracted as described before [121].
Equal amounts of protein (30 µg) were fractionated by SDS-PAGE (12% acrylamide)
and transferred to nitrocellulose membranes using a Bio-Rad immunoblot transfer
apparatus (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s
instructions. The nonspecific sites on the membrane were blocked 1 h at room
temperature with 5% nonfat dry milk in Trisbuffered saline (TBS, pH 7.6) containing
0.05% Tween-20, and then washed with TBS-Tween.

Membranes were incubated

overnight with the primary antibody (~1,000-fold diluted in TBST containing 5% bovine
serum albumin) at 4 °C and for 1 h with HRP-conjugated secondary antibody (~5,000fold diluted) at room temperature. Bands were visualized using the appropriate
horseradish

peroxidase-conjugated

secondary

antibodies

followed

by

ECL

immunoblotting detection reagents (Amersham Biosci, UK). Detection and quantitative
analysis were performed using a digitizing system (UN-SCAN-IT, Silk Scientific
Corporation).
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Electrophoretic mobility shift assays of NF-kB DNA binding

Nuclear extracts from endothelial cells were prepared as previously described
[151]. Binding reactions were performed in a 20 μL volume containing 6 μg of nuclear
protein extracts. Synthetic 5'-biotinylated complementary oligonucleotides were
purchased from Integrated DNA Technologies (Coralville, IA). Nuclear extracts were
incubated at room temperature for 20 min with biotin-labeled oligonucleotide probes
containing the enhancer DNA element for NF-B (5' -AGTTGAGGGGACTTTCCCAG
GC-3'). Gel mobility shift assay was performed to demonstrate the shifted DNA-protein
complexes for NF-B using a LightShiftTM chemiluminescent EMSA kit (Pierce,
Rockford, IL) [152]. To further exam the presence of p65 NF-B protein in the retarded
bands, EMSA followed by Western blotting (shift-Western) using an antibody against
p65 NF-B was performed.

Measurement of mRNA levels of MCP-1 and caveolin-1 by real-time reversetranscription polymerase chain reaction (Real time-PCR)

Total RNA was extracted using TRIzol Reagent (Invitrogen, NY), according to
the manufacturer’s protocol.

Reverse transcription was performed using the AMV

reverse transcription system (Promega, Madison, WI). The levels of mRNAs and the
PCR-products were then assessed by real-time PCR using 7300 Real time PCR system
(Applied Biosystems, CA). Real-time PCR samples were mixed with SYBR Green
Master Mix (Applied Biosystems CA), and MCP-1, caveolin-1 or 18S specific primers.
The sequences for human caveolin-1 gene were designed by Primer Express Software 3.0
for real-time PCR (Applied Biosystems CA), and the sequences were as followed: MCP1, 5'-CGGCTGATGAGCTACAGAAGAGT-3'(sense);5'-GCTTGGGTTCTCACAGATC
T-3' (anti-sense), Caveolin-1, 5’-TCAACCGCGACCCTAAACAC-3’(sense); 5’- CCTT
CCAAATGCCGTCAAAA-3’(anti-sense); The house keeping gene was 18S (sense, 5’TCG GAACTGAGGCCATGATT-3’, antisense, 5’-TTTCGCTCTGGTCCGTCTTG-3’).
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Statistical analysis
Values are reported as mean ± standard error of the mean (SEM) of at least three
independent groups. Data were analyzed using Sigma Stat software (Jandel Corp., Wan
Rafael, CA). One way ANOVA followed by post hoc least significant difference (LSD)’s
[153] pairwise multiple comparison procedure were used for statistical analysis of the
original data. A statistical probability of p< 0.05 was considered significant. * indicates
significant difference from control group. # Significantly different compared to cultures
treated only with Linoleic Acid.
Results
EGCG decreases caveolin-1 levels in endothelial cells

There is evidence that the lack of the caveolin-1 gene may provide protection
against the development of atherosclerosis [141]. Thus, we tested the possibility that
EGCG can down-regulated base-line levels of caveolin-1. Indeed, pretreatment of
endothelial cells with increasing concentrations of EGCG down-regulated base-line
levels of caveolin-1. Protein expression of caveolin-1 reached the lowest values in
cultures exposed to 5 and 20-30 μM EGCG (Figure 2-1).

EGCG protects against linoleic acid-induced caveolin-1 expression
Exposing endothelial cells for 6 h to linoleic acid (90 M) markedly induced
caveolin-1 (Figure 2-2A) protein expression. To test whether EGCG can down-regulate
the fatty acid-mediated induction of caveolin-1, endothelial cells were pretreated with
EGCG for 12 h, followed by exposure to linoleic acid.

A concentration-dependent

protective effect of EGCG against linoleic acid-induced caveolin-1 was observed, with a
20 M EGCG pretreatment completely blocking the fatty acid affect.
To assess the time-dependent protective effects of EGCG, endothelial cultures
were pretreated for up to 24 h with EGCG (20 M), before exposure to linoleic acid for
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an additional 6 h. The fatty acid-mediated induction of caveolin-1 was completely
blocked when cultures were pretreated with EGCG for 12 h (Figure 2-2B).

EGCG attenuates linoleic acid-mediated up-regulation of COX-2
Similar to the caveolin-1 data, exposing endothelial cells to linoleic acid markedly
induced COX-2 protein expression (Figure 2-3A). Pretreatment with 10 to 30 M EGCG
for 12 h markedly attenuated the fatty acid-induced COX-2 protein expression (Figure 23A). Similar to the caveolin-1 data, the linoleic acid-induced induction of COX-2 was
time-dependent and completely blocked after a minimum of 12 h pre-exposure to EGCG
(Figure 2-3B).

ERK1/2 and Akt but not p38 MAPK are involved in linoleic acid-induced
upregulation of COX-2

The p38 MAPK, Akt and/or ERK1/2 pathways may regulate COX-2 expression.
Therefore, endothelial cells were exposed to linoleic acid, and the levels of
phosphorylated p38 MAPK (p-p38), Akt (p-Akt) and ERK1/2 (p-ERK1/2) were assessed
by western blotting. As indicated in Figure 2-4, linoleic acid rapidly increased activation
of all kinases in a time-dependent manner, with maximum phosphorylation at 5 min for
p-p38 MAPK (Figure 2-4A), 10 min for p-ERK1/2 (Figure 2-4B), and 10 min for p-Akt
(Figure 2-4C). In order to determine which of these kinases is involved in linoleic acidmediated COX-2 expression, endothelial cells were pretreated for 1 h with specific
pharmacological inhibitors of individual kinases, such as LY294002 for Akt, SB203580
for p38 MAPK, and PD98059 for ERK1/2. Subsequently, cells were incubated with or
without 90 μM linoleic acid for 6 h. As indicated in Figure 2-5, LY294002 and PD98059,
but not SB203580, effectively blocked linoleic acid-induced activation of COX-2.

25

Caveolin-1 silencing mimics the protective effects of EGCG on linoleic acid-induced
ERK1/2 phosphorylation, COX-2 and MCP-1 expression

Knowing that the ERK1/2 and Akt pathways are involved in linoleic acidmediated induction of COX-2, we next determined the role of caveolin-1 and EGCG in
activation of these signaling cascades. In these experiments, we utilized small interfering
RNA to specifically silence caveolin-1. This procedure reduced caveolin-1 expression by
~80 % as compared with control cells without changing β-actin and total ERK1/2 levels
(Figure 2-6A). Most importantly, caveolin-1 silencing significantly protected against
linoleic acid-induced phosphorylation of ERK1/2 (Figure 2-6A); however, it did not
affect linoleic acid-mediated phosphorylation of Akt (data not shown). Pretreatment with
EGCG blocked linoleic acid-mediated phosphorylation of ERK1/2 (Figure 2-6A). Similar
to the ERK1/2 phosphorylation data, pretreatment with caveolin-1 silencing effectively
blocked linoleic acid-mediated induction of COX-2 (Figure 2-6B) and MCP-1 (Figure 26C).

Caveolin-1 silencing reduces linoleic acid-induced NF-B DNA binding

NF-B is a transcriptional regulator of COX-2 induction. Therefore, our studies
were completed by determination of the role of EGCG and caveolin-1 in linoleic acidinduced activation of NF-B. Linoleic acid significantly increased NF-B DNA binding
activity, which was blocked when cells were pre-treated with EGCG (Figure 2-7). In
addition, caveolin-1 silencing mimicked the effects of EGCG and significantly decreased
the linoleic acid-induced activation of NF-B (Figure 2-7).
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Figure 2-1 EGCG decreases caveolin-1 levels in endothelial cells.
Cells were treated with either vehicle (0.1% DMSO) or EGCG (0-30 μM) for 12 h before
determining caveolin-1 (Cav-1) expression by Western blot analysis. The Western blot
shown represents one of three experiments. Results shown represent the mean±S.E.M. of
three independent experiments. *Significantly different compared to control cultures.
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Figure 2-2 EGCG protects against linoleic-acid-induced caveolin-1 expression.
Cells were pretreated with either vehicle (0.1% DMSO) or EGCG (0-30 µM) for 12 h,
followed by exposure to linoleic acid (LA, 90 μM) for an additional 6 h (A). To assess
the time-dependent protective effect of EGCG (B), we pretreated some cultures for up to
24 h with EGCG (20 μM) before exposure to LA for an additional 6 h. Caveolin-1 (Cav-1)
protein was determined by Western blot analysis. Each Western blot shown represents
one of three experiments. Results shown represent the mean±S.E.M. of three independent
experiments. *Significantly different compared to vehicle control. # Significantly
different compared to cultures treated only with LA.
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Figure 2-3 EGCG attenuates linoleic-acid-mediated up-regulation of COX-2.
Cells were pretreated with either vehicle (0.1% DMSO) or EGCG (0-30 μM) for 12 h,
followed by exposure to linoleic acid (LA, 90 M) for an additional 6 h (A). Some
cultures were pretreated for up to 24 h with EGCG (20 μM) before exposure to LA for an
additional 6 h (B). COX-2 protein expression was determined by Western blot analysis.
Each Western blot shown represents one of three experiments. Results shown represent
the mean±S.E.M. of three independent experiments. *Significantly different compared to
vehicle control. # Significantly different compared to cultures treated only with LA.
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Figure 2-4 Linoleic acid activates p38 MAPK, Akt and ERK1/2 signaling in vascular
endothelial cells. Cells were exposed to linoleic acid (90 μM) for 5, 10 or 20 min. Total
p38 MAPK, Akt or ERK1/2 and phosphorylated p38 MAPK, Akt or ERK1/2 was
detected by Western blot using specific antibodies. The Western blots shown for each
phosphorylated kinase represent one of three experiments. Results shown represent the
mean±S.E.M. of three independent experiments. *Significantly different compared to
control cultures.
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Figure 2-5 ERK1/2 and Akt but not p38 MAPK are involved in linoleic-acid induced upregulation of COX-2. Endothelial cells were pretreated with or without the Akt inhibitor
LY294002 (LY, 10 μM for 1 h), the p38 MAPK inhibitor SB203580 (SB, 10 μM for 1 h)
or the ERK1/2 inhibitor PD98059 (PD, 20 μM for 1 h), followed by exposure to linoleic
acid (LA, 90 μM) for 6 h. Activation of COX-2 was determined by Western blot analysis.
The Western blot shown represents one of three experiments. Results shown represent the
mean±S.E.M. of three independent experiments. *Significantly different compared to
control cultures. #Significantly different compared to cultures treated only with linoleic
acid.

31

Figure 2-6 Caveolin-1 silencing mimics the protective effects of EGCG on linoleic-acidinduced ERK1/2 phosphorylation (A) and activation of COX-2 (B) and MCP-1 (C).
Endothelial cells were transfected with siRNA for caveolin-1 (Cav-1 siRNA) or with
control siRNA (Ctr-siRNA) and treated with EGCG (20 μM) for 12 h, followed by
exposure to linoleic acid (LA, 90 μM) for 10 min (A) or 6 h (B and C). Cell lysates were
probed with caveolin-1, COX-2 and β-actin or with anti-p-ERK1/2 and anti-ERK1/2.
Protein expression was determined by Western blot analysis. MCP-1 and 18S mRNA
expressions were measured by real-time PCR. Results shown represent the mean±S.E.M.
of three independent experiments. *Significantly different compared to control cultures.
#
Significantly different compared to cultures treated only with LA (Ctr-siRNA).
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Figure 2-7 Both EGCG and caveolin-1 silencing reduce linoleic-acid-induced NF-κB
DNA binding. Endothelial cells were transfected with siRNA for caveolin-1 (Cav-1
siRNA) or with control siRNA (Ctr-siRNA) and treated with EGCG (20 μM) for 12 h,
followed by exposure to linoleic acid (LA, 90 μM) for 3 h. Electrophoretic mobility shift
assay for NF-κB was performed with nuclear proteins extracted from endothelial cells.
Results shown represent the mean±S.E.M. of three independent experiments.
*Significantly different compared to vehicle control. #Significantly different compared to
cultures treated only with LA (Ctr-siRNA).
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Discussion
Flavonoids are naturally occurring polyphenolic compounds found in numerous
fruits, vegetables, and specific beverages, such as tea, grape juice, and wine. Flavonoids
have been reported to have anti-inflammatory, and antioxidant, and anti-angiogenic
activities. Some of them are known to provide protection against inflammatory diseases
such as atherosclerosis [134]. In regard to tea consumption, studies have reported up to a
58% reduction in cardiovascular risk for individuals consuming the highest compared to
the lowest amount of tea [8]. Endothelial cells line the inner layer of blood vessels and
play a critical role in the overall dynamics of vascular physiology. Activation and
subsequent dysfunction of the endothelium is considered an early event in the etiology of
cardiovascular diseases such as the pathology of atherosclerosis [123]. Endothelial cells
are constantly exposed to blood components, including food-derived lipids, toxicans, and
so forth, and are thus highly susceptible to insult and activation, leading to inflammatory
interactions with cytokines and increased uptake of activated leukocytes into the
vasculature. Endothelial cells play a critical role in the regulation of vascular tone and
other important processes which contribute to normal blood vessel function and integrity
[154].
Increased exposure of the endothelium to free fatty acid anions, metabolic events
known to activate endothelial cells [155, 156]. In the current study, endothelial cells
were activated with linoleic acid to mimic a postprandial hyperlipidemic state. We have
previously demonstrated that endothelial cell exposure to fatty acids, and especially
linoleic acid, markedly induced an endothelial inflammatory response [157]. We also
have demonstrated that the ERK1/2 signaling pathway can contribute to the effect of
linoleic acid on NF-κB-dependent transcription [121]. In the current study, inhibitors of
ERK and Akt down-regulated the linoleic acid-induced increase in COX-2 protein,
demonstrating the involvement of MAPK signaling in our model of endothelial cell
activation.
High-fat diets contribute to hypertriglyceridemia, and the vascular endothelium
can be exposed to significant levels of free fatty acids derived from lipoprotein lipasemediated hydrolysis of triglyceride-rich lipoproteins [120]. Gafencu et al [54]
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investigated fatty acid composition of caveolae from endothelial cells and indicated that
linoleic acid was about 8 to 10% of total fatty acids. Caveolae are important for
organizing and regulating the molecular interactions of multiple signaling pathways. My
results showed that linoleic acid induced both caveolin-1 and COX-2, which is significant
because of the link between caveolins (caveolae) and the pathology of atherosclerosis
[140]. Caveolin-1 has been reported to co-localize with interleukin-1beta-induced COX2 [156], suggesting the dependence of COX-2 induction on functional caveolae. Recent
evidence suggests that high-fat diets can up-regulate caveolin-1 expression in aorta of
diet-induced obese rats [158], suggesting that our fatty acid data may mimic an in vivo
response by activating COX-2.
Protective molecular mechanisms of flavonoids against endothelial activation and
inflammation are not well understood. EGCG, the most abundant and effective flavonoid
of green tea, has been shown to inhibit the expression of COX-2 and the production of
prostaglandin E2 [156, 159]. In the current study, pretreatment with EGCG blocked both
fatty acid-induced COX-2 and caveolin-1 protein expression in a time and concentrationdependent manner. Pretreatment with EGCG alone down-regulated baseline levels of the
caveolin-1 at 12 h. These data suggest that the anti-inflammatory properties of EGCG
may reside at or be initiated at the cellular level of caveolae and associated signaling
molecules. In fact, down-regulation of COX-2 by EGCG was mimicked by selective
inhibitors of kinases such as ERK and Akt. Others also have reported EGCG-mediated
down-regulation of MAPK pathways such as ERK and decreased COX-2 activity in
cancer cell lines [159, 160] and in human vascular smooth much cells [161]. MAPKs
such as ERK are known to regulate NF-B [162], and there is evidence that a decrease in
COX-2 by EGCG may be through inhibition of NF-B [163]. Indeed, our data show that
EGCG can decrease linoleic acid-induce activation of NF-B. Most importantly, our
data suggest that caveolae may provide a critical signaling platform for both induction
and protection of inflammatory genes. Further studies are needed in animal models to
examine the effects of EGCG on inflammatory genes.
EGCG was unstable in cell culture medium. EGCG is quickly oxidized,
dimerized and metabolized. Some of the metabolites of EGCG have similar or even
higher anti-oxidant and anti-inflammatory effects. The instability of EGCG is primarily
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due to its quick auto-oxidation. Several factors, such as pH, temperature, oxygen levels,
antioxidant levels, metal ions, concentrations of EGCG could affect the stability of
EGCG [164]. In our study, to prevent the quick auto-oxidation of EGCG, we flushed
EGCG extensively with N2 gas in stock solutions, and prepare fresh EGCG each time
before doing the experiments.
In summary, we provide evidence in the current study that EGCG-mediated
down-regulation of COX-2 is dependent on functional caveolin-1, the main structural
protein of caveolae.
endothelial cells [76].

This is significant, because caveolae are highly expressed in
We provide novel data, demonstrating that silencing of the

caveolin-1 gene can markedly down-regulate linoleic acid-induced phosphorylation of
ERK, MCP-1 and COX-2, suggesting that specific MAPK signaling is caveolaedependent. Data from the current study strongly support our hypothesis that membrane
domains called caveolae are a critical platform regulating inflammatory signaling
pathways that can be modulated by the interaction of bioactive compounds such as
flavonoids as well as the cellular lipid milieu. Because caveolae and caveolins have been
implicated in several human diseases and in particular vascular diseases, our data may
have implications in understanding caveolae-associated mechanisms of inflammatory
diseases and protection by bioactive food components with antioxidant and antiinflammatory properties such plant-derived flavonoids. This may in part explain the
potent protective properties of EGCG against inflammatory diseases such as
atherosclerosis.

Copyright © Yuanyuan Zheng 2010
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Chapter Three: Epigallocatechin gallate-mediated protection against tumor necrosis
factor-α-induced monocyte chemoattractant protein-1 expression is heme
oxygenase-1 dependent
This work has been published in Metabolism (Zheng Y, Toborek M, Hennig B.
Metabolism. 2010 Oct; 59 (10):1528-35).

Synopsis
Flavonoids have been suggested to protect against atherosclerosis by their antioxidant and anti- inflammatory properties. Heme oxygenase-1 (HO-1) is an enzyme that
plays an important role in the vascular system, and its induction may provide a protective
role against atherosclerosis. We hypothesize that flavonoids can down-regulate
endothelial inflammatory parameters by modulating HO-1-regulated cell signaling. We
focused on the role of HO-1 and its major metabolic product, bilirubin, on mechanisms of
tumor necrosis factor- (TNF-)-induced endothelial cell activation and protection by
the catechin epigallocatechin-gallate (EGCG). Pre-treatment with EGCG inhibited the
secretion of monocyte chemoattractant protein (MCP)-1 and the activation of activator
protein-1 (AP-1) in porcine aortic endothelial cells stimulated with TNF-. Moreover,
EGCG up-regulated the expression of HO-1 and further induced the secretion of bilirubin.
The observed anti-inflammatory effects of EGCG were mimicked by the HO-1 inducer
cobalt protoporphyrin (CoPP) and abolished by HO-1 gene silencing. These data suggest
that the protective properties of flavonoids, such as EGCG, against endothelial
inflammation may be regulated in part though induction of HO-1 and subsequent AP-1
signaling.
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Introduction
Atherosclerosis depends critically on altered behavior of the intrinsic cells of the
artery wall, in particular the endothelial cells. Inflammation plays an important role in the
development of endothelial dysfunction and atherosclerosis [165]. TNF-α is one of the
most potent pro-inflammatory cytokines [105, 166] which is highly expressed throughout
the full spectrum of atherosclerotic development [106]. TNF- can induce the activation
of the vascular endothelium, including up-regulation of monocyte chemotactic protein-1
(MCP-1) [167]. MCP-1 is a member of the CC chemokines and can be secreted by
monocytes, endothelial cells, vascular smooth muscle cells and macrophages [168]. A
bulk of evidence suggests that the inflammatory response in vascular injury involves
recruitment and activation of monocytes through activation of the MCP-1 [44], a potent
chemotactic factor for monocytes. Atherosclerosis is indeed a chronic inflammatory
disease initiated by monocyte adhesion to activated endothelial cells [169]. In both
human and experimental animal models, expression of MCP-1 have been found to be
markedly elevated in atherosclerotic lesions [170], and elevated MCP-1 serum levels are
considered a marker of inflammation in coronary artery disease patients [171]. Thus, in
the current study MCP-1 was used as an inflammation target to evaluate endothelial
function modulated by epigallocatechin-gallate (EGCG), the most abundant flavonoid
which is rich in green tea.
A bulk of evidence supports that the dietary intake of polyphenols - particularly of
flavonoids might be able to exert some beneficial vascular effects and reduce the risk for
cardiovascular morbidity and mortality. Flavonoids constitute a subclass of bioactive
compounds rich in fruits and vegetables, soy food, legumes, tea and cocoa [134]. Many
flavonoids are composed of a polyphenol structure, and these polyphenols are often
classified according to structural similarities [135]. Examples of flavonoids include
flavonols, isoflavones, flavonones, and flanan-3-ols (e.g., catechins). The review of
epidemiological and mechanistic studies supports the role of flavonoids, particularly tea
catechins, in protecting the cardiovascular system against cardiovascular disease.
Evidence suggests that habitual daily consumption of green tea is associated with a
reduced risk of coronary artery diseases, by affecting molecular mechanisms involved in
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the initiation and progression of these diseases [132, 133]. The majority of catechins in
green tea include EGCG, which has been shown to improve endothelial function and to
induce anti-inflammatory vascular events. There is strong evidence from multiple studies
that flavonoid-containing beverages and foods have such an effect. For example,
Hodgson et al showed a beneficial effect of tea consumption on endothelial function in
otherwise healthy subjects with cardiovascular risk factors [172]. Other investigators
have observed favorable vascular effects of black and green tea [173, 174]. There are two
subclasses of flavonoids in tea, the flavanols and flavonols [175] . Flavanols are found in
monomer as well as polymer form. Monomer flavanols found in tea include catechin,
epicatechin

(EC),

epigallocatechin

(EGC),

epicatechin

gallate

(ECG),

and

epigallocatechin gallate (EGCG) whereas polymer forms found in tea include theaflavins
and thearubigins. Some recent studies have showed the effects of specific catechins on
endothelial function. Widlansky et al demonstrated an improvement in brachial artery
flow-mediated dilation following acute administration of EGCG [18].
The up-regulation of hemeoxygenase (HO-1) by polyphenols may be one of the
mechanisms to explain their protection effects on vasculature inflammatory disease, such
as atherosclerosis [104]. HO-1 is an inducible rate-limiting enzyme degrading heme to
iron, carbon monoxide, and biliverdin, with the latter being quickly reduced to bilirubin
[176]. Besides the function of removing heme, the metabolic products of HO-1 have
been recognized recently to play important roles in vascular diseases [177]. For example,
proxidative and pro-inflammatory defenses are reduced during HO-1 deficiency [177].
There are three isoforms of heme oxygenases [178, 179]. Of the three isozymes, HO-2 is
the constitutive form of heme oxygeanse system, HO-3 only exist in rat, and HO-1 is
believed to be the only inducible form [179]. HO-1 is considered a protective, stressresponse enzyme, and its basal expression can be significantly up-regulated by a wide
variety of stimuli including heme, heavy metals, hydrogen peroxide, growth factors, as
well as some antioxidants [180].

Bilirubin, a product of HO-1-mediated heme

degradation, can protect lipid membranes against oxidation as efficiently as -tocopherol
and -carotene [181].

In contrast, inhibition of bilirubin production by biliverdin

reductase siRNA has been shown to increase ROS levels in primary neuronal cultures
[182]. HO-1 deficient mice showed reduced stress defense and elevated blood pressure.
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Clinical studies suggest that higher level of circulatory bilirubin is associated with
reduced risks for coronary artery diseases [183, 184]. The heme oxygenase system is an
important regulator of endothelial cell integrity and oxidative stress [185], and
dysfunctional HO-1 signaling may be pro-atherogenic.
Thus, a major objective of the present study was to explore the role of HO-1 in
mechanisms of EGCG-mediated protection of the vascular endothelium dysfunction. In
our current study, we investigated both the effects of pharmacological concentrations of
EGCG on the expression of HO-1 in endothelial cells and the involvement of specific
transcription factor-dependent pathways in this process. Our results support the
hypothesis that EGCG can exhibit anti-inflammatory properties through induction of HO1 and subsequent AP-1 signaling.
Materials and Methods
Materials

Epigallocatechin gallate (EGCG, purity >98%) was purchased from Cayman
Chemical (Ann Arbor, MI). TNF-, bilirubin and anti-β-actin antibody were obtained
from Sigma (Sigma-Aldrich, MO). Bilirubin was dissolved in 0.2 N NaOH, neutralized
to pH 7.4 using 1 N HCl, and used fresh. Cobalt protoporphyrin was purchased from
Frontier Scientific (Logan, Utah). HO-1 antibody was got from Abcam (Cambridge,
MA).

Cell culture and experimental media
Endothelial cells were isolated from porcine aortic arteries and cultured as
previously described [186]. Arteries obtained during routine slaughter were donated
from the College of Agriculture, University of Kentucky. The basic culture medium
consisted of medium 199 (M-199) (Cat. No. 31100-035; GIBCO Laboratories, NY)
containing 10% (v/v) fetal bovine serum (FBS, HyClone Laboratories, UT). Cell cultures
were grown until confluent, and then synchronized by maintaining in 1% serum
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overnight before exposure to various experimental settings.

Experimental media

contained 5% FBS and were supplemented with various concentrations of EGCG
(Cayman Chemicals, Ann Arbor, MI; purity >98%) and/or TNF- (at a final
concentration of 2 ng/ml). Time and concentration data of optimal protection of EGCG
against endothelial inflammation were conducted prior to the current study to understand
protective properties of EGCG in our cell culture model. For example, we found that the
lowest dose of EGCG which protected against TNF--induced inflammatory markers
was 30 μM. Thus, 30 μM of EGCG was used in the current study. Others have reported
similar concentrations of EGCG to decrease inflammatory markers in culture endothelial
cells [24, 187, 188]. EGCG was dissolved in DMSO; at a final concentration less than
0.1%, DMSO did not affect cell viability.

HO-1 siRNA and transfection
The HO-1 gene silencer was designed by Applied Biosystems (Lincoln Centre
Drive Foster City, CA). The sequences of HO-1 gene silencer were 5'-GCAUCUUUC
CCAACCAAGAtt-3' (sense), 5'-UCUUGGUUGGGAAAGAUGCca-3' (anti-sense). The
sequences of the control gene silencer were 5’-AAAGAGCGACUU UACACACdTdT-3'
(sense), 5’-GUGUGUAAAGUCGCUCUUUdTdT-3' (anti-sense). Cells were transfected
with control siRNA or HO-1 siRNA at a final concentration of 80 nM using GeneSilencer
(Genlantis, San Diego, CA) with Optimem I medium (Invitrogen, Carlsbad, CA). Cells
were incubated with transfection mixtures for 4 h, followed by replacement with 10%
serum medium. Cells were synchronized overnight after 48 h transfection, pre-treated
with EGCG, and subsequently treated with TNF- or vehicle.

Immunoblotting
Cells were treated with either vehicle (0.1% DMSO) or EGCG (30 µM) followed
by exposure to TNF- (2 ng/ml) for immunoblot analysis of HO-1 activation. Cell
protein was extracted as described before [121]. Equal amounts of protein (20 µg) were
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fractionated by SDS-PAGE (12% acrylamide) and transferred to nitrocellulose
membranes. The membrane was blocked 1 h at room temperature with 5% nonfat milk in
Tris-buffered saline (TBS, pH 7.6) containing 0.05% Tween-20, and then washed with
TBS-Tween. Membranes were incubated overnight with the primary antibody (1,000fold diluted in TBST containing 5% bovine serum albumin) at 4 °C and for 1 h with
HRP-conjugated secondary antibody (~5,000-fold diluted) at room temperature. Bands
were visualized using the appropriate horseradish peroxidase-conjugated secondary
antibodies followed by ECL immunoblotting detection reagents (Amersham Biosciences,
Buckinghamshire, England).

Electrophoretic mobility shift assays of AP-1-DNA binding
Nuclear extracts from endothelial cells were prepared as previously described
[151]. Synthetic 5'-biotinylated complementary oligonucleotides were purchased from
Integrated DNA Technologies (Coralville, IA). Nuclear extracts were incubated at room
temperature for 20 min with biotin-labeled oligonucleotide probes containing the
enhancer DNA element for AP-1 (5'bio-CGCTTGATGACTCAGCCGGAA-3'). Gel
mobility shift assay was performed to demonstrate the shifted DNA-protein complexes
for AP-1 using a LightShiftTM chemiluminescent EMSA kit (Pierce, Rockford, IL).
Reactions using 200-fold molar excess of unlabeled oligonucletide probes were
performed to demonstrate the specificity of the shifted DNA-protein complexes for AP-1.
[152].

Real-time reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA),
according to the manufacturer’s protocol. Reverse transcription was performed using the
AMV reverse transcription system (Promega, Madison, WI). The levels of mRNAs and
the PCR-products were then assessed by real-time PCR using 7300 Real time PCR
system (Applied Biosystems, CA). Samples were mixed with SYBR Green Master Mix
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(Applied Biosystems CA), and MCP-1, HO-1 or -actin specific primers. The sequences
for porcine HO-1, MCP-1, and -actin gene were designed by Primer Express Software
3.0 for real-time PCR (Applied Biosystems CA), and the sequences were as followed:
MCP-1,5'-CGGCTGATGAGCTACAGAAGAGT-3'(sense);5'-GCTTGGGTTCTCACA
GATCT-3' (anti-sense), HO-1, 5’-AGGTCACCCGAGAAGGCTTT-3’(sense), 5’-TAGA
CCGGGTTCTCCTTGTTGT-3’(anti-sense). The house keeping gene was -actin, 5’TCATCACCATCGGCAACG-3’(sense), 5’-TTCCTGATGTCCACGTCG-3’(anti-sense).

Measurement of bilirubin production
After plating, cells were treated with TNF- and EGCG or vehicle. All further
manipulations were carried out in a dark room. After incubation, 0.5 ml of each culture
supernatant was collected and 250 mg BaCl2. 2H2O was added. After vortexing, 0.75 ml
benzene was added; then, tubes were vortexed vigorously leading to the formation of a
relatively stable milky-white emulsion. After centrifugation (13000g, 30min), the upper
benzene layer was collected and the absorbance was measured at 450 nm with a reference
wavelength at 600 nm using a SpectraMaxPro M2 spectrophotometer (Molecular Devices,
Sunnyvale, CA). In a separate tube, 0.5 ml of fresh culture medium was processed in the
same way and the benzene layer was collected and used as a blank. The quantity of
bilirubin produced was calculated using a molar extinction coefficient of bilirubin
dissolved in benzene, with the molar extinction coefficient being e450 =27.3mM-1cm-1
[189].

MCP-1 determination
Cells were seeded in 6 or 24 well microplates and grown to confluence. After
treatment, supernatants of cell cultures were collected into microcentrifuge tubes (Isc
BioExpress, UT), centrifuged at 4 °C to remove cellular debris and then stored at -80 °C.
MCP-1 levels were assessed using a MCP-1-specific enzyme immunoassay [190] (BD
Biosciences, CA) following the manufacturer’s protocol with minor modification. A
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microplate spectrophotometer SpectraMaxPro M2 (Molecular Devices Corporation, CA)
was used to read the plate at 450 nm.

Transfection of antisense oligodeoxynucleotides into porcine endothelial cells
The

sequences

of

the

phosphorothioate

double-stranded

antisense

oligodeoxynucleotides (ODNs) against the AP-1 binding site used in this study was AP-1
decoy ODN, 5’-AGCTTGTGAGTCAGAAGCT-3’and AP-1 mismatched ODN, 5’AGCTTGAATCTCAGAAGCT-3’. The double-stranded ODNs were prepared from
complementary single-stranded phosphorothiolate-bonded oligonucleotides. The ODNs
were annealed for 1 h, while the temperature descended from 80 to 25 °C. DNA derived
from endothelial cells was precomplexed with the PLUS reagents (Life Technologies,
Rockville, MD) at room temperature for 15 min. The pre-complexed DNA was combined
with diluted LipofectAMINE reagent (Life Technologies), mixed and incubated for 15
min at room temperature. While complexes were forming, medium with serum-free
transfection medium were replaced. Then DNAPLUS Lipofect AMINE reagent complex
was added to each well containing fresh medium, and cells were incubated for 5 h. After
incubation, complete medium with serum was added. After transfection for 48 h, cell
extracts were prepared for Real-time PCR analysis [191].

Monocyte adhesion assay
Human THP‐ 1 monocytes were activated with TNF‐ (10 min) and loaded with
the fluorescent probe calcein (Molecular Probes, Carlsbad, CA). Porcine aortic
endothelial cells were treated with EGCG and TNF‐. Monocytes were added to treated
endothelial cell monolayers and incubated (30 min), allowing for monocyte adhesion.
Unbound monocytes were washed away, and the monolayer was fixed with 1%
glutaraldehyde. Attached fluorescent monocytes were counted using a fluorescent
microscope (Olympus IX70, Center Valley, PA).
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Statistical analysis
Values are reported as mean ±standard error of the mean (SEM) of at least three
independent groups. Data were analyzed using Sigma Stat software (Jandel Corp., Wan
Rafael, CA). One way ANOVA followed by post hoc least significant difference (LSD)’s
[153] pairwise multiple comparison procedure were used for statistical analysis of the
original data. A statistical probability of p< 0.05 was considered significant.

Results
Both EGCG and CoPP induce HO-1 and inhibit TNF-α-induced MCP-1 expression
Cells were treated either with vehicle, EGCG, or cobalt protoporphyrin (CoPP) in
the presence or absence of TNF- before determining MCP-1 mRNA and HO-1 protein
expression.

Exposure to TNF- markedly induced MCP-1 mRNA expression, which

was significantly reduced by pre-treatment with wither EGCG or the potent HO-1 inducer
CoPP (Figure 3-1). Most importantly, both CoPP and EGCG significantly induced HO-1
levels in endothelial cells (Figure 3-2). In contrast, exposure to TNF- neither induced
HO-1 expression nor affected HO-1 expression induced by both CoPP and EGCG (Figure
3-2).
HO-1 silencing prevents EGCG-mediated protection against TNF-α-induced MCP-1
up-regulation and monocyte adhesion
Small interfering RNA was utilized to specifically silence HO-1 expression in
endothelial cells. Cells were transfected with siRNA for HO-1 (HO-1 siRNA) or with
control siRNA (Ctr-siRNA), and silencing of HO-1 was significant, as shown by
diminished levels of HO-1 protein (Figure 3-3A). Subsequently, cells were pre-treated
with EGCG, followed by exposure to TNF-.

TNF- markedly increased MCP-1

mRNA and protein expression, independent of HO-1 silencing (Figures 3-3B and C). In
control siRNA cells, pre-treatment with EGCG markedly inhibited MCP-1 up-regulation,
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and monocyte adhesion induced by exposure to TNF-. In contrast, HO-1 silencing
reversed the inhibitory effects of EGCG both at the message and protein level (Figure 33B and C). And similarly, the absence of HO-1 also diminished the protection effects of
EGCG against monocyte adhesion (figure 3-4).

EGCG induces bilirubin levels in endothelial cells, and supplemental bilirubin
reduces TNF-α-induced up-regulation of MCP-1, and monocyte adhesion
HO-1 has potent anti-inflammatory effects, which may be exerted through the
generation of bilirubin [192]. Therefore, we tested whether this enzymatic product of
HO-1 could mediate the potential protective effects in TNF-α-stimulated endothelial cells.
In addition to up-regulating HO-1, both CoPP and EGCG also significantly induced the
secretion of bilirubin (Figures 3-5A and 3-5B). Furthermore, supplemental bilirubin
markedly quenched the TNF--stimulated induction of MCP-1, and monocyte adhesion
(Figure 3-7A and 3-7B). As expected, HO-1 silencing not only abolished the induction
of HO-1, but also the cellular ability for the production of bilirubin as induced by EGCG
and CoPP in Ctr-siRNA cells (Figures 3-5A and 3-5B).
The effect of EGCG on DNA binding of AP-1 and subsequent MCP-1 induction is
dependent on functional HO-1
To assess whether activation of AP-1 is implicated in TNF--induced MCP-1
gene transcription, cells were stimulated with TNF- after transfection with AP-1 decoy
ODN (an inhibitor of AP-1) and AP-1 mismatched ODN (negative control). AP-1 decoy
ODN partially inhibited TNF--induced MCP-1 mRNA expression (Figure 3-6A),
suggesting that AP-1 is involved in TNF--induced MCP-1 production. Similar to its
ability to quench TNF--mediated induction of MCP-1, supplemental bilirubin also
significantly reduced AP-1 DNA binding activity (Figure 3-6B).

Furthermore, the

protective effects of EGCG through AP-1 signaling appear to be dependent on functional
HO-1.

Pre-treatment with EGCG markedly suppressed AP-1 DNA-binding activity

(Figure 3-6C). HO-1 siRNA transfection not only blocked EGCG-induced production of
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bilirubin (Figure 3-5B), but it also reversed the inhibitory effect of EGCG against TNF-induced AP-1 activation (Figure 3-6C).
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Figure 3-1 EGCG and CoPP inhibit TNF-α-induced MCP-1 expression. Cells were
pretreated with either vehicle (0.1% DMSO), EGCG (30 µM) or CoPP (10 µM) for 2 h,
followed by exposure to TNF-α (2 ng/ml) for an additional 6 h. MCP-1and β-actin
mRNA expressions were measured by real time-PCR. Results shown represent the mean
± SEM, n=3; *Significantly different compared to vehicle control. #Significantly different
compared to cultures treated only with TNF-α.
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Figure 3-2 EGCG and CoPP induce HO-1 levels in endothelial cells. Cells were treated
with either vehicle (0.1% DMSO), EGCG (30 µM), or CoPP (10 µM) in the presence or
absence of TNF-α (2 ng/ml) for 4 h before determining HO-1expression by western blot
analysis. The western blot shown represents one of three experiments. Results shown
represent the mean ±SEM, n=3; *Significantly different compared to control cultures.
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Figure 3-3 HO-1 silencing prevents EGCG-mediated protection against TNF-α-induced
up-regulation of MCP-1. Endothelial cells were transfected with siRNA for HO-1 (HO-1
siRNA) or with control siRNA (Ctr-siRNA) and treated with EGCG (30 µM) for 2 h,
followed by exposure to TNF-α (2 ng/ml) for 6 h. Figures 3-3A demonstrates successful
silencing. MCP-1 mRNA expressions were measured by real time-PCR (Figure 3-3B).
Media were collected, and MCP-1 levels were measured by enzyme immunoassay
(Figure 3-3C). Results shown represent the mean ± SEM, n=3; *Significantly different
compared to respective control cultures. #Significantly different compared to cultures
treated only with TNF-α (Ctr-siRNA).
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Figure 3-4 HO-1 silencing prevents EGCG-mediated protection against TNF-α-induced
monocyte adhesion. Endothelial cells were transfected with siRNA for HO-1 (HO-1
siRNA) or with control siRNA (Ctr-siRNA). Human THP-1 monocytes were loaded with
the fluorescent probe calcein. Endothelial cells were pre-treated with EGCG (30 µM) for
2 h and followed by the exposure to TNF‐ng/ml) for 6 h. Monocytes were added to
treated endothelial cell monolayers and incubated allowing for monocyte adhesion.
Attached fluorescent monocytes were counted using a fluorescent microscope. Results
shown represent the mean ± SEM, n=3; *Significantly different compared to control
cultures. #Significantly different compared to cultures treated only with TNF-α (CtrsiRNA).
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Figure 3-5 EGCG induces bilirubin levels in endothelial cells. Endothelial cells were
transfected with siRNA for HO-1 (HO-1 siRNA) or with control siRNA (Ctr-siRNA) and
cells were treated with either vehicle (0.1% DMSO), EGCG (30 µM), or CoPP (10 µM)
for 4 h before determining HO-1 and bilirubin production (3-5A and B). Results shown
represent the mean ±SEM, n=3; *Significantly different compared to control cultures.
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Figure 3-6 The effect of EGCG on DNA binding of AP-1 and subsequent MCP-1
induction is dependent on functional HO-1. Endothelial cells were stimulated with TNFα for 4 h after transfection of AP-1 decoy ODN and mismatched-ODN. Subsequently,
MCP-1 mRNA levels were measured (Figure 3-6A). Cells also were pretreated with
either vehicle (H2O) or bilirubin (0-10 µM) for 2 h, followed by exposure to TNF-α for
an additional 4 h. Electrophoretic mobility shift assay for AP-1 was performed with
nuclear proteins (Figure 3-6B). In separate experiments, endothelial cells were
transfected with siRNA for HO-1 (HO-1 siRNA) or with control siRNA (Ctr-siRNA) and
treated with EGCG for 2 h, followed by exposure to TNF-α for 4 h. Electrophoretic
mobility shift assay for AP-1 was performed with nuclear proteins (Figure 3-6C). Results
show represent the mean ±SEM, n=3; *Significantly different compared to vehicle
control. #Significantly different compared to cultures treated only with TNF-α (CtrsiRNA).
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Figure 3-7 Bilirubin inhibits TNF-α-induced MCP-1 expression and monocyte adhesion.
Cells were pretreated with bilirubin (1-10 µM), followed by exposure to TNF-α (2 ng/ml)
for 6 h. MCP-1 (Figure 3-7A) and monocyte adhesion (Figure 3-7B) were measured.
Results shown represent the mean ±SEM, n=3; *Significantly different compared to
vehicle control. #Significantly different compared to cultures treated only with TNF-α.
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Discussion
Flavonoids have anti-inflammatory properties and thus can provide protection
against inflammatory diseases such as atherosclerosis [134]. EGCG, the most abundant
catechins derived from green tea, have various bioactive properties associated with
antioxidant, anti-angiogenesis, and anti-inflammatory functions, which all are relevant to
the prevention and treatment of cardiovascular diseases [193]. Endothelial cells line the
inner layer of blood vessels and play a critical role in the overall dynamics of vascular
physiology. Activation and subsequent dysfunction of the endothelium is considered an
early event in the etiology of cardiovascular diseases such as the pathology of
atherosclerosis [123]. Studies suggest that EGCG, the major polyphenolic constituent in
green tea, has anti-inflammatory effects, such as inhibition of cytokine-induced VCAM-1
expression [24]. However, detailed mechanisms of the anti-inflammatory properties of
EGCG associated with endothelial cell function are not well defined.
In the present study, we used TNF- a major pro-inflammatory cytokine
stimulate cells to induce endothelial inflammation. Our data suggest that pre-treatment
with EGCG inhibited TNF--induced superoxide production and endothelial secretion of
MCP-1, a critical chemokine responsible for the recruitment of monocytes to the intima
[194]. Oxidative stress refers to disrupted redox equilibrium between the production of
free radicals and the ability of cells to protect against damage caused by these molecules.
Moreover, EGCG also inhibited the activation of TNF--induced AP-1, which has been
recognized as one of the required transcription factors for MCP-1 gene induction besides
NF-B [195, 196]. In the current study, the DNA-binding activity of AP-1 increased
after TNF- stimulation along with an increase in MCP-1 mRNA. We also found that
transfection of an AP-1 decoy ODN into the cells down-regulated the TNF--induced
MCP-1 mRNA levels. Thus, TNF- induced MCP-1 production in our cell culture
system was partially dependent on AP-1 activation. In addition to AP-1, TNF- also
induced NF-B DNA binding. However, EGCG only inhibited TNF--induced AP-1
activation, with little effect on NF-B DNA binding. Others also have reported that
EGCG did not influence TNF--stimulated NF-B in human endothelial cells [24],
suggesting that EGCG more specifically alters AP-1 signaling in endothelial cells.
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HO-1 over-expression can inhibit pathological activities including inflammation,
vascular proliferation, and chronic transplant rejection [197, 198]. It has been reported
that overexpression of the HO-1 protein inhibits lipopolysaccharide-induced iNOS
expression and NO production [199, 200]. Furthermore, the HO-1 protein is essential for
the anti-inflammatory effects of IL-10 and 15-deoxy-delta 12, 14-prostaglandin J2 [201,
202].

Our data support the hypothesis that EGCG can provide protection against

endothelial inflammation through induction of HO-1 gene expression.

In fact, the

observed anti-inflammatory effects of EGCG were mimicked by the HO-1 inducer cobalt
protoporphyrin (CoPP), and abolished by HO-1 siRNA transfection. In the current study,
treatment with CoPP, inhibited TNF--induced MCP-1 up-regulation, suggesting that
HO-1 may be an important target in endothelial cells against inflammation and the further
development of atherosclerosis. We investigated the relationship between HO-1, ROS
production, AP-1 activation, and monocyte adhesion in TNF-α-stimulated endothelial
cells. Cells were pre-treated with EGCG and then exposed to TNF-α. Our data suggest
that the EGCG-mediated HO-1 protein expression interferes with TNF-α-induced
superoxide production and AP-1 activation. Moreover, blocking of HO-1 expression by
transfection with siRNA reversed the suppressive effects of EGCG in terms of AP-1
translocation and MCP-1 upregulation in TNF-α-treated endothelial cells.
Although the molecular targets of HO-1 are not fully clear, our study
demonstrates that HO-1-mediated signaling is a critical mechanisms during the reduction
of endothelial inflammation by EGCG. In addition, our data also suggest that HO-1 acts
upstream of AP-1 activity, supporting a previous study demonstrating that HO-1
expression has a direct effect on the activation of the proinflammatory AP-1 pathway
[203]. EGCG could induce HO-1 indirectly through other signaling mechanisms, such as
via induction of NO, because it has been reported that phenolics can increase NO [204,
205] and that NO can induce HO-1 [180, 206]. To further investigate the role of HO-1
in EGCG-mediated protection against endothelial cell activation, we explored effects of
bilirubin, a specific enzymatic metabolite of HO-1. Serum bilirubin levels are inversely
associated with insulin resistance and other complications of metabolic syndrome [207],
and exogenous administration of bilirubin can promote endothelial cell survival [208].
In the current study, EGCG significantly induced bilirubin levels in endothelial cultures,
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which was blocked in HO-1-silenced cells. Supplemental bilirubin also significantly
inhibited the expression of MCP-1 and monocyte adhesion in a concentration-dependent
manner.

Moreover, similar to EGCG, supplemental bilirubin inhibited the TNF-α-

stimulated AP-1 activation.
Taken together, our data support the hypothesis that the protection effects of
EGCG against TNF--induced DNA binding of AP-1 and subsequent MCP-1 induction,
monocyte adhesion are dependent on functional HO-1.

Furthermore, data from the

current study also strongly support our hypothesis that HO-1 expression and bilirubin
secretion induced by flavonoids such as EGCG can inhibit TNF--stimulated MCP-1 upregulation, and AP-1 activation associated with vascular endothelial inflammation. This
may in part explain the potent protective properties of EGCG against inflammatory
diseases such as atherosclerosis. Our findings add to the growing body of evidence for
the beneficial effects of green tea consumption on improving cardiovascular health.

Copyright © Yuanyuan Zheng 2010
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Chapter Four: EGCG stimulates Nrf2 and heme oxygenase-1 via caveolin-1
displacement
This work has been submitted for publication (Zheng et al., Atherosclerosis, 2010).

Synopsis
Flavonoids, such as the tea catechin epigallocatechin-gallate (EGCG), can
protect against atherosclerosis by decreasing vascular endothelial cell inflammation.
Plasma microdomains called caveolae are important in vesicular transport and the
regulation of signaling pathways associated with vascular diseases. We hypothesized that
caveolae play a role in the uptake and transport of EGCG and mechanisms associated
with the anti-inflammatory properties of this flavonoid. To test this hypothesis, we
measured EGCG levels in caveolae-enriched domains and caveolin-1 gene silencing cells.
We also explored the effects of EGCG on the induction of Nrf2 and HO-1 in endothelial
cells with or without functional caveolae. EGCG rapidly accumulated in caveolae, which
was associated with caveolin-1 displacement from the plasma membrane towards the
cytosol. Furthermore, caveolin-1 gene silencing significantly reduces the uptake of
EGCG in endothelial cells within 30 min. Treatment with EGCG activated Nrf2 and
increased HO-1 expression and cellular production of bilirubin. Similar to EGCG
treatment, silencing of caveolin-1 by siRNA technique also resulted in upregulation of
Nrf2, HO-1 and bilirubin production. These data suggest that caveolae may play a role in
the uptake and transport of EGCG. EGCG-mediated displacement of caveolin-1 may
associate with the activation of Nrf2/HO-1 pathway.
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Introduction
Diets high in polyphenols (e.g., flavonoids) are associated with a reduced risk of
chronic diseases, such as cardiovascular diseases, by affecting molecular mechanisms
involved in the initiation and progression of these diseases [132, 133]. Flavonoids
constitute a subclass of bioactive compounds rich in fruits and vegetables, soy food,
legumes, tea and cocoa [134]. Green tea consumption has been shown to be significantly
greater in healthy subjects compared to those with coronary artery disease [209],
suggesting that green tea might be protective against coronary atherosclerosis [210].
Catechins are the major constituents of the polyphenols in green tea, and the most
abundant catechin in green tea is epigallocatechin-3-O-gallate (EGCG). Even though the
consumption of flavonoids such as EGCG are known to improve endothelial cell function,
and thus reduce cardiovascular risk [211], protective mechanisms are not clear but may
be linked to caveolae signaling.
There is increasing evidence that caveolae play a critical role in the pathology of
vascular diseases and that the lack of the caveolin-1 gene may provide protection against
the development of atherosclerosis [212]. Caveolae are plasma-membrane domains that
are highly enriched in cholesterol and sphingolipids. One of the functions attributed to
endothelial caveolae is their ability to transfer molecules from the lumen of blood vessels
to the sub-endothelial space [73]. Unlike clathrin-mediated endocytosis, internalization
through caveolae involves complex signaling [74]. Caveolin-1 is a major scaffolding
protein constituent of caveolae that participates in vesicular trafficking and signal
transduction, and caveolin-1 can cycle between the plasma membrane and several
intracellular compartments [75]. Caveolae are particularly abundant in endothelial cells,
where they are believed to play a major role in the regulation of endothelial vesicular
trafficking as well as the uptake of lipids and related lipophilic compounds possibly
including bioactive food components such as flavonoids by means of endocytosis [76,
77].
Protective mechanisms of flavonoids may include upregulation of heme
oxygenase-1 (HO-1) [104], an enzyme localized to plasma membrane caveolae [213].
HO-1 is an inducible enzyme which catalyzes the oxidative degradation of heme by
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degrading heme to iron, carbon monoxide and biliverdin, with the latter being quickly
reduced to bilirubin [176]. The heme oxygenase system is an important regulator of
endothelial cell integrity and oxidative stress [185], and dysfunctional HO-1 signaling
may be a pro-atherogenic event. HO-1 can be upregulated by EGCG [104], and we have
recently demonstrated that EGCG-mediated protection against TNF-α induced MCP-1
expression is HO-1 dependent [214].
Recent genome-wide analysis demonstrated that the transcription factor NF-E2related factor (Nrf2) can regulate numerous genes that are involved in the cytoprotective
response against oxidative stress [215]. For example, the induction of the antioxidant
gene HO-1 is associated with nuclear translocation of Nrf2 and subsequent
transactivation of an antioxidant response element in the promoter region of HO-1 [216].
There is evidence that flavonoids like EGCG can induce HO-1 via activation of Nrf2
[104, 217]. Since HO-1 is an enzyme localized to plasma membrane caveolae [213], we
were interested in the possible involvement of functional caveolae in EGCG-mediated
stimulation of Nrf2 and HO-1. We recently reported a role of caveolin-1 in EGCGmediated protection against linoleic acid-induced endothelial cell activation [77],
suggesting that caveolae may provide a regulatory platform of our observed effects of
EGCG on stimulation of Nrf2 and HO-1.

Materials and Methods
Cell culture and experimental media
Primary endothelial cells were isolated from porcine aortic arteries and cultured
as previously described [186]. The basic culture medium consisted of medium 199 (M199) (Cat. No. 31100-035; GIBCO Laboratories, NY) containing 10% (v/v) fetal bovine
serum (FBS, HyClone Laboratories, UT). Experimental media contained 5% FBS and
were supplemented with EGCG (Cayman Chemicals, Ann Arbor, MI; purity >98%).
EGCG was dissolved in DMSO; at a final concentration less than 0.1%, DMSO did not
affect cell viability.
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Detergent- free purification of caveolae-rich membrane domains
Caveolae-rich membrane domains were isolated as previously reported [218],
with minor mortifications. Briefly, cells were plated in 150 mm plates. After treatment,
cells were washed with PBS and lysed with 2 ml of ice-cold MES-buffered saline [MBS;
25mM MES (morpholineethanesulfonic acid, pH 6.5), 150 mM NaCl] containing 500
mM Na2CO3. Following homogenization and sonication, homogenates were adjusted to
45% sucrose by addition of 2 ml of 90% sucrose prepared in MBS and placed at the
bottom of an ultracentrifuge tube, and overlaid with a discontinuous sucrose gradient (5
ml of 35% sucrose and then 3 ml of 5% sucrose were added). The gradient samples were
then centrifuged at 39,000 rpm (260,000g) for 16 h using a SW41 rotor (Beckman
Instruments, Palo Alto, CA). Twelve 1 ml fractions were collected, and aliquots of each
fraction were subjected to SDS-PAGE and immunoblotting to assess caveolin-1.
Immunoblot analysis of HO-1, caveolin-1 and Nrf2 protein expression
Cells were treated with either vehicle (0.1% DMSO) or EGCG (30 µM)
followed by immunoblot analysis of HO-1 protein activation. To detect the effect of
EGCG and caveolin-1 gene silencing on Nrf2 accumulation in nucleus, both nuclear and
cytosol protein extracts from endothelial cells were prepared as previously described
[151].

Western blots were visualized using the appropriate horseradish peroxidase-

conjugated secondary antibodies followed by ECL immunoblotting detection reagents
(Amersham Biosciences, Buckinghamshire, England).

Caveolin-1 siRNA and transfection
The caveolin-1 gene silencer was designed by Dharmacon (Lafayette Colorado)
according to previously described methods [150]. The sequences of caveolin-1 gene
silencer were 5'-CCAGAAGGGACACACAGUUdTdT-3' (sense), 5'-AACUGUGUGU
CCCUUCUGGdTdT-3' (anti-sense). The sequences of the control gene silencer were 5’AAAGAGCGACUUUACACACdTdT-3' (sense), 5’-GUGUGUAAAGUCGCUCUUU
dTdT-3' (anti-sense). Cells were transfected with control siRNA or caveolin-1 siRNA at
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a final concentration of 80 nM using GeneSilencer (Genlantis, San Diego, CA) with
Optimem I medium (Invitrogen, Carlsbad, CA). Cells were incubated with transfection
mixtures for 4 h and then replaced with 10% serum medium. Cells were synchronized
overnight after 48 h transfection, and then treated with EGCG.
Electrophoretic mobility shift assays of Nrf2-ARE-DNA binding
Nuclear extracts from endothelial cells were prepared as previously described
[151]. Synthetic 5'-biotinylated complementary oligonucleotides were purchased from
Integrated DNA Technologies (Coralville, IA). Nuclear extracts were incubated at room
temperature for 20 min with biotin-labeled oligonucleotide probes containing ARE, the
enhancer DNA element for HO-1 (5' bio-AGATTTTGCTGAGTCACCAGTCCC-3')
[219]. Gel mobility shift assay was performed to demonstrate the shifted DNA-protein
complexes Nrf2-ARE using a LightShiftTM chemiluminescent EMSA kit (Pierce,
Rockford, IL) [152]. Reactions using 200-fold molar excess of unlabeled oligonucletide
probes were performed to demonstrate the specificity of the shifted DNA-protein
complexes for Nrf2. To further examine the presence of Nrf2 protein in the retarded
bands, EMSA was performed and followed by Western blotting (shift-Western) using an
antibody against Nrf2.
Quantification of EGCG by LC/MS/MS
After treatment with EGCG, cells were washed twice in cold PBS. Then cells
were scraped in 2 ml cold PBS containing 100 l 20% ascorbic acid solution and 50 pmol
internal standards (ethyl gallate). Cell suspensions or aqueous samples were diluted with
4 ml ethyl acetate, vortexed and then centrifuged for 10 min at 3,500 rpm. Organic layers
were removed and evaporated to dryness under a gentle N2 stream in a water bath. Dry
extracts were reconstituted with 50:50 water:acetonitrile and injected into LC/MS/MS.
The mass spectrometer included an Applied Biosystems/MDS SCIEX 4000-Qtrap hybrid,
linear ion trap, triple quadrupole MS (Applied Biosystems, Foster City, CA), and the
liquid chromatograph was a Prominence UFLC from Shimadzu Corp., Columbia, MD.
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Polyphenols were separated using an Eclipse XDB C8, 5 µM, 4.6 X 150 mm (Agilent)
column.
Measurement of bilirubin production
After plating, cells were treated with TNF- and EGCG or vehicle. All further
manipulations were carried out in a dark room. After incubation, 0.5 ml of each culture
supernatant was collected and 250 mg BaCl2. 2H2O was added. After vortexing, 0.75 ml
benzene was added; then, tubes were vortexed vigorously leading to the formation of a
relatively stable milky-white emulsion. After centrifugation (30 min at 13,000g), the
upper benzene layer was collected and the absorbance was measured at 450 nm with a
reference wavelength at 600 nm using a SpectraMaxPro M2 spectrophotometer
(Molecular Devices, Sunnyvale, CA). In a separate tube, 0.5 ml of fresh culture medium
was processed in the same way and the benzene layer was collected and used as a blank.
The quantity of bilirubin produced was calculated using a molar extinction coefficient of
bilirubin dissolved in benzene, with the molar extinction coefficient being e450 =27.3mM1

cm-1 [189].

Statistical analysis
Values are reported as mean ± standard error of the mean (SEM) of at least three
independent groups. Data were analyzed using Sigma Stat software (Jandel Corp., Wan
Rafael, CA). One way ANOVA followed by post hoc least significant difference (LSD)’s
pairwise multiple comparison procedure were used for statistical analysis of the original
data. A statistical probability of P< 0.05 was considered significant.

Results
EGCG treatment stimulates caveolin-1 displacement
We tested the hypothesis that EGCG can co-localize with caveolae and displace
caveolin-1. Caveolae enriched fractions were isolated using a detergent-free sucrose
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density gradient centrifugation method, followed by protein analysis using Western blot.
In control cultures, and as expected, caveolin-1 protein was most enriched in fractions 4
and 5 (Figure 4-1). In contrast, treatment with EGCG induced displacement of caveolin1 in endothelial cells. At 0.5 h and 1 h, caveolin-1 translocated from fractions 4 and 5
toward fractions 6 to 8, and after 2 h, caveolin-1 recycled back mainly in plasma
membrane lipid rafts (fractions 4 and 5). These data suggest that exposure to EGCG
leads to caveolin-1 displacement, and that caveolae may transport EGCG from the
plasma membrane toward the cytosol or intracellular compartments.

EGCG quantification in endothelial cells
To further understand the stability and cell uptake of EGCG by endothelial cells,
we quantified EGCG by LC/MS/MS analysis. Cells were exposed to EGCG for up to 4 h.
After a peak at 30 min, EGCG levels in the media decreased, with only about 20% of the
parent flavonoid remaining at 4 h (Figure 4-2A). Cell-associated levels were maximal at
30 min and then declined in parallel with observed media levels (Figure 4-2B). These
results confirmed that EGCG is easily auto-oxidized and quickly metabolized [164].
Results in Figure 4-2C demonstrate that endothelial cells can become enriched with
EGCG in a dose-dependent manner.

EGCG accumulates in caveolae-enriched fractions
To further investigate the role of caveolae in the uptake and transport of EGCG,
we measured EGCG levels in both caveolae-rich membrane fractions and non-caveolae
fractions after treatment with EGCG for 5, 10, 20 or 40 min. EGCG levels showed in the
figures were normalized by the amount of proteins in caveolae-rich domains and noncaveolae fractions respectively. EGCG markedly accumulated in caveolae-rich
membrane domains at 10 min (Figure 4-3A), with a subsequent relocation into the noncaveolae cell fractions (Figure 4-3B).
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Caveolae silencing reduces cellular EGCG uptake
To explore a potential role of caveolae in EGCG uptake, cells were transfected
with caveolin-1 specific siRNAs [153]. Compared to cells with functional caveolae,
cellular levels of EGCG at 30 min were significantly decreased after silencing caveolin-1
(Figure 4-4). This trend continued but was not significant at 1 h after EGCG exposure.

Cavelin-1 silencing induces upregulation of HO-1 and bilirubin production
HO-1 has potent anti-inflammatory effects, which may be exerted through the
generation of bilirubin [192]. Therefore, we tested the effects of caveolin-1 gene
silencing on HO-1 expression and bilirubin production in endothelial cells. The results
showed that both EGCG treatment and caveolin-1 gene silencing significantly induced
HO-1 levels (Figure 4-5A). Similar to the HO-1 data, both EGCG and caveolin-1 gene
silencing significantly induced the cellular secretion of bilirubin (Figure 4-5B).

Caveolin-1 silencing increases both nuclear accumulation of Nrf2 and Nrf2-ARE
binding
It has been suggested that the regulation of Nrf2 transcriptional activation of
phase II antioxidant enzymes (e.g., HO-1) relies on subcellular distribution rather than
induction of this transcription factor through de novo synthesis [220]. Activation of Nrf2
results in increased accumulation of Nrf2 in the nucleus [221]. Thus, we determined
nuclear levels of Nrf2 in both control and EGCG-treated cells with or without functional
caveolae to investigate whether induction of HO-1 is associated with nuclear
translocation of Nrf2. As shown by immunoblot analysis in Figure 4-6A, Nrf2 protein
levels in the nucleus significantly increased in cells treated with EGCG. Caveolin-1
silencing independently increased Nrf2, with no additive effects due to cellular exposure
to EGCG. Nrf2 protein in the cytosol was unaffected by EGCG treatment or caveolin-1
silencing (Figure 4-6B). Since Nrf2 activates transcription activities of its genes through
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binding specifically to the ARE found in the promoters of target genes [222, 223], we
also studied the effects of EGCG on Nrf2-ARE binding. In agreement with the observed
nuclear accumulation of Nrf2, Nrf2-ARE specific HO-1 promoter binding was also
significantly enhanced both in EGCG treated or caveolin-1 silenced cells (Figure 4-6C,
there were two retarded bands, Western Blotting with Nrf2 antibody following the EMSA
assay demonstrated the upper band was Nrf2-ARE complex).
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Figure 4-1 EGCG treatment stimulates caveolin-1 translocation. Endothelial cells were
treated with vehicle (0.1% DMSO) or EGCG (30 µM) for 0.5-2 h. Caveolae enriched
fractions were isolated by detergent-free sucrose gradient centrifugation method. Then
the expression of caveolin-1 was measured by Western blot. Fractions 1 to 3 containing 5%
sucrose, fractions 4 to 8 containing 35% sucrose, fractions 9 to 12 containing 45%
sucrose. Result shown represents one of three experiments.
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Figure 4-2 EGCG quantification in endothelial cells was performed by LC/MS/MS
analysis. Endothelial cells were treated with EGCG (30 µM) for 0.5-4 h, and EGCG
levels were measure by LC/MS/MS in the media (Figure 4-2A) and cells (Figure 4-2B).
In separate experiments, endothelial cells were treated with increasing concentrations of
EGCG (0-180 µM) for 1 h, before measuring cellular levels of EGCG (Figure 4-2C).
Results shown represent the mean ±SEM of three independent experiments.
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Figure 4-3 EGCG accumulates in caveolae-enriched fractions. Endothelial cells were
treated with EGCG (30 µM) for 5-40 min. Caveolae were isolated by detergent-free
sucrose density gradient centrifugation method. EGCG levels in caveolae-rich domains
(Figure 4-3A) and non-caveolae fractions (Figure 4-3B) were measured by LC/MS/MS.
EGCG levels shown in the figure were normalized against protein levels in caveolae or
non-caveolae fractions, respectively. Results shown represent the mean ± SEM of three
independent experiments.
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Figure 4-4 Caveolae take up EGCG in endothelial cells. Endothelial cells were
transfected with siRNA for caveolin-1 (Cav-1 siRNA) or with control siRNA (Ctr-siRNA)
and treated with EGCG (30 µM) for 30 min and 1 h. EGCG levels in the whole cells were
measured by LC/MS/MS. Results shown represent the mean ± SEM of five independent
experiments.
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Figure 4-5 Cavelin-1 silencing induces upregulation of HO-1 and bilirubin production.
Endothelial cells were transfected with siRNA for caveolin-1 (Cav-1 siRNA) or with
control siRNA (Ctr- siRNA) and then treated with vehicle (0.1% DMSO) or EGCG (30
µM) for 6 h, before determining HO-1 protein expression (Figure 4-5A) and bilirubin
production (Figure 4-5B). Results shown represent the mean ± SEM of three
independent experiments. *Significantly different compared to control cultures.
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Figure 4-6 Caveolin-1 silencing increases both nuclear accumulation of Nrf2 and Nrf2ARE binding. Endothelial cells were transfected with siRNA for caveolin-1 (Cav-1
siRNA) or with control siRNA (Ctr- siRNA) and then treated with vehicle (0.1% DMSO)
or EGCG (30 µM) for 3 h, before determining Nrf2 protein expression both in nucleus
(Figure 4-6A) and cytosol (Figure 4-6B). Electrophoretic mobility shift assay for Nrf2ARE binding was performed with nuclear proteins (Figure 4-6C). Following the EMSA
assay, Western blotting with the Nrf2 antibody demonstrated the upper band to be the
Nrf2-ARE complex. Results shown represent the mean ± SEM of three independent
experiments. *Significantly different compared to control cultures.
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Discussion
There is evidence that catechins derived from green tea, such as EGCG, have
antioxidant, anti-inflammatory and anti-angiogenesis properties and thus can provide
protection against inflammatory diseases such as atherosclerosis [224]. In the current
study we provide evidence that the vascular antioxidant and anti-inflammatory properties
of EGCG may be regulated through the interaction of this flavonoid with caveolae. Lipid
rafts, and especially caveolae, have been recently recognized as signal transduction hubs
[225, 226], and may be involved in the selective cellular uptake of plasma-derived
material [227, 228] and possibly resveratrol [229] and other polyphenols such as EGCG.
It has been reported that EGCG is taken up by some lipid raft proteins in the
membrane, such as laminin receptor (LamR), and that it further alters the composition of
membrane domains as well as changes in some signaling pathways [230]. Besides
specific interactions with some genes and proteins, another important pathway that may
function in EGCG action is direct targeting on lipid rafts. Structure and composition
alterations of the lipid raft by polyphenols can dramatically affect signaling pathways,
such as MAP kinases pathway [80, 231]. Our LC/MS/MS results suggest that EGCG can
concentrate in the caveolae fractions before further cellular redistribution. In fact,
following cellular exposure, EGCG quickly enriched in caveolae membrane domains,
with a subsequent relocation to non-caveolae fractions. This suggests that caveolae may
play a role in the uptake and transport of EGCG from plasma membrane lipid rafts
towards the cytosol in endothelial cells. To confirm the role of caveolae in the uptake of
EGCG, endothelial cells were silenced with caveolin-1-siRNA. Results showed that
caveolin-1 gene silencing significantly decreased cellular uptake of EGCG at 30 min, i.e.,
at a time point when EGCG was markedly enriched in the caveolae fractions of normal
endothelial cells.
Caveolae usually have a specific lipid composition, which appears to be required
for the specific functional relevance of caveolae-associated proteins [232, 233]. In line
with these functional characteristics, caveolae can provide a regulatory platform for
proinflammatory signaling associated with vascular diseases such as atherosclerosis [234].
For example, enriching endothelial cells with docosahexaenoic acid can affect caveolae-
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associated nitric oxide synthase activity [235], a process which may be linked to
caveolae-mediated endocytosis [236]. We also found previously that pretreatment with
EGCG can block fatty acid-induced caveolin-1 expression in a time and concentration
dependent manner [77]. In the current study, we provide evidence that EGCG can
stimulate caveolin-1 displacement from the plasma membrane towards the cytosol. Most
importantly, the ability of EGCG to displace caveolin-1 may be associated with its ability
to activate Nrf2 and to increase HO-1 expression and cellular production of bilirubin.
We have reported recently that EGCG-mediated protection against TNF-αinduced monocyte chemoattractant protein-1 expression is HO-1 dependent [214], and
we now provide data which demonstrate that caveolae play an important role in the
uptake and transport of EGCG, as well as protection against endothelial inflammation
through the induction of Nrf2-dependent HO-1. Our results clearly show that in addition
to EGCG, caveolin-1 gene silencing can induce HO-1 protein expression and thus upregulate the production of bilirubin. Both HO-1 and bilirubin have been reported to play
critical roles in cellular and tissue defenses against oxidative stress and inflammation
[237]. HO-1 over-expression can inhibit pathological activities, including inflammation,
vascular proliferation, and chronic transplant rejection [197, 198]. It has been reported
that over-expression of the HO-1 protein inhibits lipopolysaccharide-induced iNOS
expression [199, 200].

Furthermore, the HO-1 protein is essential for the anti-

inflammatory effects of IL-10 and 15-deoxy-delta 12, 14-prostaglandin J2 [201, 202].
Since Nrf2 is the major transcription factor of HO-1, we investigated the role of
Nrf2 in EGCG or caveolin-1 gene silencing mediated activation of HO-1. Nrf2 is a
leucine zipper transcription factor which plays an essential role in the up-regulation of
phase II anti-oxidant genes, including HO-1 [102]. Once migrated to the nucleus, Nrf2
forms heterodimers with small Maf proteins and subsequently binds to the cis-acting
antioxidant response element (ARE). This leads to the transcriptional activation of a
number of genes that encode the phase II detoxifying or antioxidant enzymes, such as
NQO1, GST, GCL, and HO-1 [103]. In the current study, EGCG treatment significantly
induced nuclear accumulation of Nrf2 as well as enhancement of Nrf2-ARE binding at
the HO-1 promoter site. In contrast, in caveolin-1-silenced cells, both accumulation of
Nrf2 as well as enhancement of Nrf2-ARE binding at the HO-1 promoter site were
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already elevated in untreated cells, with EGCG having no additional effect on stimulation
of Nrf2. This suggests that caveolin-1 displacement within functional caveolae may be
associated with EGCG-mediated induction of Nrf2 in endothelial cells.
EGCG can increase the nitric oxide level in endothelial cells [238]. Furthermore,
Ramirez-Sanchez et al demonstrated that (-)-epicatechin treatment induced eNOS
uncoupling from caveolin-1, thus activating eNOS function [239]. Thus, there is a
possibility that our observed EGCG-mediated upregulation of Nrf2 is regulated in part
through caveolae-dependent eNOS/NO signaling [240]. It is well known that caveolin-1
is a negative regulator for eNOS activity [241]. Thus, EGCG-activated caveolin-1
displacement may lead to its disassociation with eNOS, leading to NO production.
Moreover, NO has been found to increase HO-1 induction in various cell types [242]. It
has also been reported that NO can stimulate Nrf2 translocation and activation in the
vascular endothelium [243-245]. It is not clear how flavonoids like EGCG enter the cell
to modulate gene expression; however, some endocytotic process might be involved [74].
In fact, it has been demonstrated that caveolae-mediated endocytosis can play a critical
role of in regulating eNOS activation in endothelial cells [236]. More studies are needed
to fully understand the link between protective properties of dietary flavonoids such as
EGCG and caveolae-mediate-cellular signaling.
In summary, we provide evidence that caveolae play a role in the uptake and
transport of EGCG and mechanisms may associate with the anti-inflammatory properties
of this flavonoid. Functional caveolae may be a prerequisite for EGCG to cause caveolin1 displacement and to initiate the protective signaling cascade.
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Chapter Five: Summary
Conclusion
Endothelial dysfunction is a critical early event in the development of
atherosclerosis. The inflammatory reaction in endothelial cells is regulated by complex
interactions. Long term exposure to cardiovascular risk factors will ultimately exhaust
those protective anti-inflammatory factors. Through increased expression of adhesion
molecules, activated endothelial cells stimulate monocytes attachment and migration into
sub-endothelial space, where the monocytes differentiate into macrophages and by taking
up modified lipids further become foam cells. Smooth muscle cells proliferate and
migrate from tunica media to intima responding to cytokines secreted by damaged
endothelial cells. Finally, these inflammatory events cause the formation of a fibrous cap
covering the fatty streak, an accumulation of lipid-laden cells in the sub-endothelial
spaces. In more advanced stages of atherosclerosis, formation of fibrous plaque and
lesions will ultimately lead to an acute clinical event caused by plaque rapture and
thrombosis [44, 45]. Since the initial stage of atherosclerosis is the critical time point
when nutrition (e.g. flavonoids) modulation could have the most beneficial effects, the
research in this dissertation focused on the early events of atherosclerosis, including the
role of caveolae and heme oxygenase-1 (HO-1) on dietary flavonoid EGCG-mediated
protection against pro-inflammatory cytokine tumor necrosis factor (TNF)-α or linoleic
acid-induced activation of endothelial cells.
One major link of the three chapters of this dissertation is the bioactive green tea
flavonoid EGCG. Chapter Two focused on caveolae-associated mechanisms of
inflammatory diseases and protection by EGCG. Chapter Three focused on the role of
HO-1 in EGCG-mediated protection against endothelial inflammation. Since it has been
reported that deletion of caveolin-1 protects against oxidative lung injury via upregulation of HO-1, and caveolin-1 may interact with and modulate HO-1 activity in
endothelial cells [213, 246], Chapter Four focused on the correlations between caveolae
and HO-1 and their roles in EGCG-mediated anti-inflammation effects.
Linoleic acid, the essential omega-6 fatty acid in the American diet is proinflammatory and pro-atherogenic. It favors oxidative modification of LDL cholesterol,
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and increases platelet aggregation. Previous research has shown that linoleic acid
potentiated TNF-α-induced endothelial cell activation [120]. EGCG, the most abundant
bioactive polyphenol of green tea, has been suggested to have an anti-inflammatory
function by inhibiting cytokine-induced VCAM-1 expression in HUVEC [24]. EGCG
has also been shown to inhibit the expression of COX-2 and the production of
prostaglandin E2 [156, 159]. Caveolae, the plasma membrane invaginations, have been
implicated in several human diseases and in particular vascular diseases. Caveolae are
particularly abundant in endothelial cells, where they are believed to play a major role in
the regulation of endothelial vesicular trafficking as well as the uptake of lipids and
related lipophilic compounds [76]. In Chapter Four, evidence is provided that caveolae
may also regulate vascular trafficking of bioactive food components such as flavonoids.
There is evidence that fatty acids can alter localization and function of caveolaeassociated signaling proteins in mouse colonic mucosa [56]. Besides the role of vesicular
transport, caveolae harbor an array of cell signaling molecules, and numerous enzymes
involved in endothelial cell dysfunction and inflammation [140]. Considering these
findings led to the hypothesis that caveolae possibly play a role in EGCG mediated
protection against endothelial cell activation. The data support the hypothesis that EGCG
inhibited linoleic acid-induced endothelial inflammation. The current research provided
novel data demonstrating that EGCG down-regulated the base-line level and linoleic
acid-induced caveolin-1, the main structural protein of caveolae. The results further
suggested that silencing of the caveolin-1 gene expression by small-interference RNA
technique markedly down-regulated linoleic acid-induced COX-2 and MCP-1 expression
indicating that caveolae may be a critical platform regulating inflammatory signaling
pathways that can be modulated by the interaction of bioactive compounds such as
flavonoids.
The HO system plays a critical role in cellular and tissue self-defense against
oxidative stress and inflammation. HO-1 is the inducible isoform degrading heme to
carbon monoxide (CO), ferrous (Fe2+) and biliverdin, the latter being subsequently
converted into bilirubin. Excess heme catalyzes the formation of reactive oxygen species,
which cause endothelial dysfunction. Therefore, the HO system may be recognized as a
protector of endothelial cell integrity. Bilirubin has strong anti-oxidant properties and
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thus can scavenge reactive oxygen species, inhibit NADPH oxidase activity [86], and
preserve endothelial integrity, in part by increasing the bioavailability of NO [87]. Higher
serum bilirubin levels are associated with a reduced risk of coronary artery disease [89].
The dissertation hypothesized that the flavonoid EGCG might down-regulate endothelial
inflammatory parameters by modulating HO-1-regulated cell signaling. Thus, a focus of
this study was on the role of HO-1 and its major metabolic product, bilirubin, on
mechanisms of TNF--induced endothelial cell activation and protection by EGCG. The
data support the hypothesis that EGCG can protect against TNF--induced DNA binding
of AP-1, subsequent MCP-1 induction, and monocyte adhesion. Moreover, EGCG upregulated the expression of HO-1 and further induced the secretion of bilirubin. The
observed anti-inflammatory effects of EGCG were mimicked by the HO-1 inducer cobalt
protoporphyrin (CoPP) and abolished by HO-1 gene silencing. The data suggested that
the protective properties of flavonoids, such as EGCG, against endothelial inflammation
might be regulated in part through induction of HO-1 and subsequent AP-1 signaling.
This in part explains the protective properties of EGCG against inflammatory diseases
such as atherosclerosis.
Caveolin-1 ablation not only prevented linoleic acid-induced endothelial activation,
but also protected against environmental toxin PCB77-induced MCP-1 up-regulation in
endothelial cells [247]. To further understand the molecular mechanisms underlying the
anti-inflammatory effects of caveolin-1 ablation, caveolin-1 was silenced in endothelial
cells, and its effect on Nrf2/HO-1 cellular self-defense system was investigated. The
results clearly showed that caveolin-1 gene silencing induced HO-1 protein expression, as
well as up-regulation of the production of bilirubin. Nrf2 is a redox-sensitive
transcription factor. Most genes encoding phase II enzymes, such as some detoxifying or
antioxidant enzymes, contain a common DNA sequence called antioxidant response
elements (ARE) that are located in their promoter regions. Nrf2 is the major transcription
factor that regulates gene expression under the control of ARE. These Nrf2 regulated
phase II enzymes play key roles in cellular defense by enhancing the removal of
cytotoxic electrophiles or reactive oxygen species [248]. Thus, induction of Nrf2-ARE
signaling provides a cellular self-defense against a variety of electrophilic compounds,
reactive toxicants and oxidants [124]. This research provided novel data which suggest
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that either EGCG or caveolin-1 silencing can induce up-regulation of HO-1 expression
and subsequent bilirubin induction, and that these events require functional Nrf2.
One of the functions attributed to endothelial caveolae is their ability to transfer
molecules by endocytosis. It has been reported that some polyphenols such as resveratrol
can be transported by caveolae [229]. Cavolin-1, the major constituent of caveolae
participates in the process of endocytosis. Caveolin-1 constantly recycles between the
plasma membrane, cytosol and intracellular compartments. Caveolin-1 could directly
bind to some lipophilic compounds, such as some fatty acids, fat-soluble vitamins and
polyphenols. Unlike clathrin-mediated endocytosis, internalization by caveolae involves
complex signaling transduction [74]. Caveolae are highly enriched in membrane binding
proteins, such as H-ras, src-family tyrosine kinases, heterotrimeric G-proteins, eNOS, etc.
[139, 249, 250]. Caveolins can bind and functionally regulate (mostly inhibit) these
caveolae-localized molecules [251-256]. When caveolin-1 moves away from the plasma
membrane, some of these co-localized signaling molecules are released and activated. It
was hypothesized that EGCG might cause caveolae displacement and thus modulate
those signaling proteins associated with caveolae. The data clearly showed that EGCG
rapidly accumulated in caveolae, which was associated with caveolin-1 translocation
from plasma membrane towards cytosol. More interestingly, EGCG failed to further
activate Nrf2 in caveolin-1 silenced cells. This suggests that EGCG-mediated Nrf2
activation may need caveolae function perhaps by caveolin-1 displacement. It has been
reported that caveolae-mediated endocytosis induced eNOS activation in endothelial cells
[236]. It is well known that nitric oxide is a strong inducer of Nrf2 and HO-1 [243-245].
Furthermore, EGCG can increase the nitric oxide level in endothelial cells [238]. Thus,
the hypothesis is that EGCG-mediated caveolin-1 translocation may activate eNOS, and
further activate Nrf2/HO-1. More work is needed to further demonstrate this hypothesis.
Taken together, these data suggest that EGCG-induced caveolin-1 displacement may
reduce endothelial inflammation. This study provides a novel target through which
EGCG functions to protect against inflammatory diseases such as atherosclerosis.
The quantification of EGCG in endothelial cells was also successfully performed
by using LC/MS/MS. In most of the in vitro experiments which have been published, the
cell cultures were treated with 20-100 µM of EGCG or other tea polyphenols. These
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concentrations are much higher than those observed in human plasma (plasma
concentrations are usually lower than 1 µM) [257]. Sang et al [164] reported that EGCG
concentration decreased rapidly, with a half-life of approximately 30 min, and that EGCG
dimers and other products were formed. Several factors, such as pH, temperature, oxygen
levels, antioxidant levels, metal ions and the concentration of EGCG could affect the
stability of EGCG. To further understand the amount of EGCG taken up by endothelial
cells, in the study, EGCG levels in endothelial cell cultures were measured by
LC/MS/MS in the laboratory of Dr. Morris at the University of Kentucky. The results
showed that in the culture media, EGCG levels decreased over the course of time. Cellassociated EGCG levels were maximal at 30 minutes and then declined in parallel with
the medium levels. These data suggest that EGCG was quickly auto-oxidized and
metabolized.

Concentration studies also demonstrated that the uptake of EGCG by

endothelial cells was increased in a dose- dependent manner.
Taken together, the data provide implications in understanding HO-1 and
caveolae-associated mechanisms of inflammatory diseases and protection by bioactive
food components with antioxidant and anti-inflammatory properties such as the green tea
flavonoid EGCG. The data provided in this dissertation may in part explain the protective
properties of EGCG against inflammatory diseases such as atherosclerosis.

Future directions
It is well known that EGCG is quickly metabolized both in cell culture and in the
human body. Once absorbed into the intestine, EGCG undergoes glucuronidation,
sulfation, and methylation [258]. Research found that in mouse tissues, 55-90% of EGCG
is conjugated [259]. Thus, in future studies, it is tempting to set up experiments to
identify what is being formed during EGCG metabolism and which metabolites may have
similar or even higher anti-oxidant or anti-inflammatory properties. Further research
could extract EGCG metabolic products from the serum of animals which have been
treated with EGCG and further test the protective effects of these metabolites against
endothelial inflammation and atherosclerosis.
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The data suggest that caveolin-1 silencing and subsequent up-regulation of HO-1
may involve the transcription factor Nrf2. Also, a direct interaction between HO-1 and
caveolin-1 has been established by immunocytochemistry and coimmunoprecipitation
[260].

Research also found the location of HO-1 protein in the detergent-resistant

membrane fraction, where it appears to be in the caveolae, as caveolin-1 itself is localized
to the structure [213]. This dynamic caveolin constantly recycles between the plasma
membrane, endosomes, and trans-Golgi network. Caveolae may associate with HO-1 to
undergo internalization and recycling [213]. In addition, studies demonstrated that
activation of mitogen-activated protein kinases (MAPKs) contributes to the induction of
HO-1 [261]. These pathways may affect endothelial cell function and are likely to be
activated by substances interacting with or disrupting caveolae. Thus, future studies of a
more detailed involvement of the interactions between caveolae and HO-1 in endothelial
cells could be tested.

This dissertation provided novel data which suggested EGCG-induced upregulation of Nrf2/HO-1 might be associated with EGCG-induced caveolin-1
translocation. But the mechanism is not clear. The hypothesis is that EGCG-induced
caveolin-1 displacement may cause activation of eNOS, which further activates Nrf2. To
further demonstrate this hypothesis, eNOS, p-eNOS protein expressions, eNOS activities,
and NO production should be measured. An eNOS inhibitor could be used to demonstrate
the role of NO on Nrf2 activation by EGCG. Furthermore, the protein interactions
between caveolin-1 and eNOS in the presence or absence of EGCG should also be tested
by immunoprecipitation or immunocytochemistry. Moreover, besides eNOS, it is
possible that some other caveolae bound signaling proteins (e.g. H-ras, src-family
tyrosine kinases) also participate in the caveolae-associated induction of Nrf2/HO-1. It
will be interesting to know which caveolae co-localized molecules are involved in the
mechanisms underlying the protection effects of EGCG against endothelial inflammation.
After investigating the molecular and cellular mechanisms by which upregulation of HO-1 may protect against endothelial dysfunction in cultured cells and how
flavonoids protect against endothelial dysfunction, studies in vivo are needed to confirm
this hypothesis. These studies will allow us to determine if HO-1 is necessary for the
protective actions of flavonoids against vascular oxidative stress and inflammation, and
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whether the crosstalk between caveolae and Nrf2/HO-1 as influenced by EGCG helps to
prevent against atherosclerosis in vivo. One might hypothesize that flavonoids, such as
EGCG, could ameliorate ApoE knockout-induced endothelial dysfunction partially via
up-regulation of HO-1. ApoE knockout mice, ApoE-/-/caveolin-1-/- and ApoE-/-/HO-1-/double knockout mice could be used in future studies and treated with flavonoids or
vehicle. Endothelial functions (such as endothelium dependent vasodilation, Ca2+
dependent NOS enzyme activity, cGMP and cAMP levels), atherosclerosis lesion areas,
oxidative stress levels, and phase II anti-oxidant enzyme activities could be determined
throughout these studies.

EGCG

TNF-α /LA
Changing
Caveolae function

HO-1/Bilirubin↑

Endothelial
Inflammation

Nrf2 ↑

Figure 5-1 Crosstalk between the caveolae and Nrf2/HO-1/bilirubin pathways during
EGCG-mediated protection against endothelial inflammation
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Appendix Methods
 1. Primary culture of porcine pulmonary artery and aortic endothelial cells
Porcine pulmonary arteries and aortas are obtained from University of Kentucky
Agriculture Department.
Cell culture growth media
M199 – total 400 ml
Penn‐Strep – 4 ml
L‐glutamine – 4 ml
Amino Acids – 4 ml
Fetal Bovine Serum (FBS) – 40 ml (10%)
Hanks
Water – 2 L autoclaved/filtered
KCL – 0.8 g
KH2PO4 – 0.12 g
NaCl – 16 g
NaHCO3 – 0.7 g
Na2HPO4 * 7 H2O – 0.18 g
D‐glucose – 2 g
Phenol Red – 0.02 g
Reviving the cells (Cells are frozen in high concentrations of DMSO, so it must be
thawed in media immediately)
1. Fill 10 ml of 37 °C M199 medium (10% FBS) in a 15 ml tube.
2. Take 1 ml of the M199 media and add to cryovial containing the frozen cells, pipette
repeatedly and once some of the cells thaw, transfer to the 15 ml tube. Continue until all
thawed cells are in suspension.
3. Centrifuge (5 min at 2,500 rpm at 37 °C)
4. Discard supernatant, resuspend in fresh media, and repeat centrifugation
5. Seed it to T75 flask
6. Change media after 24 hours
Freezing the cells
Cocktail:
FBS ‐ 2 ml
M199 10% FBS – 13 ml
28% DMSO (1.75 ml DMSO + 4.5 ml M199) – 5 ml
1. Trypsinize Cells
2. Spin cells in 10ml of media in 15 ml tube, and centrifuge (2,500 rpm for 5 min)
3. Resuspend pellet in 2 ml freezing cocktail
4. Split into 2 cyrovials (1 ml each)
5. Cover with white foam
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6. ‐20°C overnight
7. ‐80°C overnight
8. Put it into liquid nitrogen
 2. Protein isolation
a) Whole cell extraction
Lysis buffer (100 ml)
Tris‐HCl – 1 M 2 ml (pH ~7.4, final concentration: 20 mM,)
Tris + H2O up to 50 ml, stir, add HCl (2M), adjust pH, add rest of H2O
NaCl – 1 M 15 ml (Final concentration150 mM)
Triton X‐100 – 10% (v/v) 5 ml (final 0.5% liq)
PMSF – 10 mg/ml (DMSO/EtOH) 1 ml (final 0.1 mg/ml)
NP‐40 500 µl (final 0.5% liq)
EDTA (0.1 M) 1 ml (final 1 mM)
Leupeptin (1 mg/ml) DMSO 250 µl (final 2.5 µg/ml)
Pepstatin (1 mg/ml) DMSO 1 ml (final 10 µg/ml)
Na3VO4 (sodium orthovanadate) 500 µl (final 1 mM)
Protease inhibitor 200 mM
Make lysis buffer (‐) then add proteinase inhibitors just before using lysis buffer
Isolate proteins
1) Wash the cells with ice-cold PBS for 3 times
2) Add 3ml of ice‐cold PBS and scrape the cells. Transfer to conical tube
3) Add another 3ml PBS to the plate and collect the remaining cells
4) Pellet it down at 2,500 rpm for 10 min at 4ºC
5) Pour off supernatant
6) Add 200‐300 µl of lysis buffer and vortex it for 30 sec and put on ice for 2 min (5‐8
times repeat)
7) Keep on ice and incubate for at least 20 min
8) Vortex and then centrifuge at 12,000 rpm for 15 min at 4ºC
9) Take the supernatant out and make aliquots of it
10) Freeze in dry ice then store at ‐80ºC
Whole cell extraction by sonication
Lysis buffer
Water
Tris HCl (pH 7.5) 20 mM
NaCl 150 mM
EDTA 1 mM
EGTA 1 mM
Triton X‐100 1%
Sodium pyrophosphate 2.5 mM
‐glycerophosphate 1 mM
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To add just before:
Na3VO4 1 mM
Leupeptin 1 μg/ml
PMSF 1 mM
1) Remove media and rinse with cold PBS 2 times
2) Scrape cells in PBS into centrifuge tube on ice
3) Centrifuge 2,500 rpm 10 min at 4 °C
4) Remove all PBS
5) Add protease inhibitors to lysis buffer
6) Add 100 μl to pellet, put in eppendorf tube
7) Sonicate samples on ice 3x for 5 seconds at 65%/sec
8) Microcentrifuge for 10 min at 14,000 rpm at 4 °C
9) Transfer supernatant to new tube, store at ‐80 °C
b) Nuclear extraction
Buffer A
Water – total 10 ml
HEPES 10 mM pH 7.9
KCl 10 mM
EDTA 0.1 mM
DTT 1 mM
PMSF 0.5 mM
Buffer B
HEPES 20 mM
NaCl 0.4 M
EDTA 1 mM
DTT 1 mM
PMSF 1 mM
1) Wash cells with ice cold PBS for 3 times
2) Add 3ml cold PBS, scrape the cells
3) Centrifuge 10 min at 13,000 rpm at 4 °C
4) Resuspend in 400 μl of buffer A
5) 15 min incubation on ice
6) Add 25 μl 10% NP‐40
7) Wait 5 min until cells are lysed
8) Centrifuge 14,000 rpm for 1 min
9) Resuspend with 25‐50 μl of buffer B
10) Nuclei lysed by shaking vigorously at 4 °C for 5 min
11) Collect clear supernatant, store at -80°C
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 3. Western blot
Preparing sample
1) Dilute sample with water to 1 µg/µl
2) Add 5 µl of sample loading buffer (contains 400 µl 2x SSB and 100 µl DTT, 1 M)
3) Boil at 100ºC for 6 min
4) Put on ice until loading
5) Load 6 µl of the marker and 24 µl of sample
Preparing the gel
1. Separation gel
1) Prepare or 10 ml/gel
2) Prevent apparatus from leaking
3) After pouring, cover with ethanol ~20 min to solidify
4) Rinse with H2O for 3 times
2. Stacking gel
1) Put into less than 5 ml/gel
2) Fill up to glass, then insert comb (~1 cm between comb and separation gel)
3) 30 min to solidify
Running the gel
1) Prepare the running buffer (900 ml H2O + 100 ml of 10x buffer)
2) Put the gel in
3) Load the samples (including marker)
4) Run at 80V until samples get to resolving buffer and then 100 V for 1 to 2 h
Transfer onto membrane
1) Prepare: sponges, holders, ice cold transfer buffer
2) Cut the filter paper and membrane – slightly smaller than the sponges
3) Add transfer buffer in the dish
4) Put into a. sponge b. filter paper c. gel (cut off stacking, cut side to tell orientation)
d. membrane e. filter paper f. sponge (roll with tube)
5) Put in apparatus
6) Add buffer
7) Add the box with ice and cover with the whole thing
8) Run at 340mV for 90min
Blocking with milk
1) Prepare 5% (g/100ml) milk in TBST
2) Put membrane in the milk/TBST
3) Shake 30-60 min at room temperature
4) Rinse with TBST
5) Shake in TBST for 5min, 3 times
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Binding of the primary antibody
1) Add certain amount of primary antibody in 5% milk/TBST, 2 h incubation at RT or 4 º
C overnight
2) Wash 3x 10 min with TBST
Binding of the secondary antibody
1) Put the secondary antibody into 5% milk/ TBST
2) Shake for 1 h at RT
3) Wash 4 x 15 min with TBST
Visualization
1) Discard the TBST
2) Mix ECL WB Detection Reagents (Amersham Biosci)
3) 1.5 ml of reagent A + 1.5 ml of reagent B
4) Distribute the mixture evenly by pipette on the membrane
5) Let sit for 1-2 minute
6) Dry the membrane gently on a kim wipe
7) Put the membrane into the plastic case in the cassette
8) Put the film inside (Amersham‐ Hyperfilm)
9) Exposure (time dependent on the signal)
10) Develop the film
 4. Monocyte cell (THP-1) adhesion
Growth media
RPMI – total 400 ml (Gibco 11875 with L‐glutamine)
Glucose (2.5 g/L) – 4 ml of 0.25 g/ml stock
HEPES (10 mM) – 4 ml of 1 M stock
Sodium Pyruvate (1 mM) – 4 ml of 100 mM stock
Penn‐Strep (1%) – 4 ml of 100x stock
FBS – 10%
β‐mercaptoethanol (50 μM) – 1.75 μl of 14.3 M stock
1) Treat cells 6-8 hrs with compound, TNF-α as a positive control (10 ng/ml)
2) Activate THP-1 with TNF- (10 ng/ml) for 10 min (wash 3 times)
3) Count 50,000 monocyte cells/well
4) Resuspend in 1.0 ml 1% media
5) Load cells with calcein (3µl/ml)
6) Incubate 37ºC for 15 min
7) Spin to get rid of excess calcein, wash with media
8) Spin again, resuspend in 50 µl/well media
9) Aspirate off endothelial treatment media, add 1ml media
10) Add 50 µl monocytes to each well
11) Incubate 37ºC for 30 min
12) Gently wash unbound monocytes off with 1% media
13) Add 200 µl 1% Glutaraldehyde (made with PBS containing Ca and Mg)
14) Room Temp for 30 min
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15) Wash plate w/ PBS
16) Count using confocal microscope
 5. RNA isolation
1) Discard treatment media; add 800 μl Trizol to cells
2) Scrape into 1.5 ml microcentrifuge tube, incubate 5 min at RT
3) Add 0.2 ml chloroform, shake tubes vigorously by hand for 15 seconds and incubate
them at RT for 5 min
4) Centrifuge at 12,000 g for 15 min at 4 °C
5) Transfer aqueous phase to a fresh tube
6) Add 0.5 ml isopropyl alcohol to precipitate RNA, incubate samples at RT for 10 min
7) Centrifuge at 12000 g for 10 min at 4 °C and then remove supernatant
8) Add 1 ml 75% ethanol to pellet, vortex, and centrifuge at 7,500 g for 5 min
9) Remove ethanol, air dry
10) Dissolve RNA in RNase‐ free water (~20 μl), Boil at water bath 55 °C for 10 min
11) Store at ‐ 80 °C
 6. Chemiluminescent EMSA (LightShift® Chemiluminescent EMSA Kit 20148,
protocol is adapted from Pierce Web Site)
a). Anneal oligos
1. Spin down the lyophilized oligos and resuspend in TE buffer.
2. Dilute each oligo to 1 pmol/μl in TE.
3. Mix 1 μl of each forward and reverse oligo in 48 μl of TE to a final concentration of
20 fmol/μl.
4. Incubate the oligos at 95°C for 2 min. Switch off the heat block and let it cool down to
room temperature.
5. Keep oligos on ice and store at -20°C.
b). Prepare and pre-run gel
5X TBE pH 8.3
450 mM Tris
450 mM boric acid
10 mM EDTA
1. Prepare a 4 -6% polyacrylamide gel in 0.5X TBE.
2. Fill with 0.5X TBE to just above the bottom of the wells. Flush wells and preelectrophorese the gel for 30-60 minutes. Apply 100 V for an 8 x 8 x 0.1 cm gel.
3. Pre-electophoresing.
c). Binding reaction
1. Thaw all binding reaction components, and place them on ice. Avoid excessive
warming of DNA probes.
2. Prepare complete sets of 20 μl binding reactions for the Control EBNA System and/or
the Test System (Table 1).
3. Incubate binding reactions at room temperature for 20 minutes.
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4. Add 5 μl of 5X Loading buffer to each 20 μl binding reaction, pipetting up and down
several times to mix. Do not vortex or mix vigorously.
d). Electrophorese binding reactions
1. Switch off current to the electrophoresis gel.
2. Flush the wells and then load 20 μl of each sample onto the polyacrylamide gel.
3. Switch on current (set to 100 V for 8 x 8 x 0.1 cm gel) and electrophorese samples
until the bromophenol blue dye has migrated approximately 3/4 down the length of the
gel.
e). Electrophoretic transfer of binding reactions to nylon membrane
1. Soak nylon membrane in 0.5X TBE for at least 10 min.
2. Sandwich the gel and nylon membrane in a clean electrophoretic transfer unit. Use
0.5X TBE cooled to ~10ºC with a circulating water bath. Use very clean forceps and
powder-free gloves, and handle the membrane only at the corners.
3. Transfer at 380 mA (~100V) for 30 min. Typical transfer times are 30-60 min at 380
mA using a standard tank transfer apparatus for mini gels (8 x 8 x 0.1 cm).
4. When the transfer is complete, place the membrane with the bromophenol blue side up
on a dry paper towel. Allow buffer on the membrane surface to absorb into the membrane.
This will only take a min. Do not let the membrane dry.
f). Cross-link transferred DNA to membrane
Cross-link at 120 mJ/cm2, use a commercial UV-light cross-linker instrument equipped
with 254 nm bulbs (45-60 second exposure using the auto cross-link function).
g). Detect biotin-labeled DNA by chemiluminescence
1. Warm the Blocking Buffer and the 4X Wash Buffer to 37-50°C in a water bath.
2. Block the membrane by adding 20 ml of Blocking Buffer and incubate for 15 min with
gentle shaking.
3. Prepare conjugate/blocking buffer solution by adding 66.7 μl Stabilized StreptavidinHorseradish Peroxidase Conjugate to 20 ml Blocking Buffer (1:300 dilution).
4. Decant blocking buffer and replace it with the conjugate/blocking solution. Incubate
membrane in the conjugate/blocking buffer solution for 15 min with gentle shaking.
5. Prepare 1X wash solution by adding 40 ml of 4X Wash Buffer to 120 ml water.
6. Transfer membrane to a new container and rinse it with 20 ml wash solution.
7. Wash membrane 4X 5 min each in 20 ml of wash solution with gentle shaking.
8. Transfer membrane to a new container and add 30 ml of Substrate Equilibration Buffer.
Incubate membrane for 5 min with gentle shaking.
9. Prepare Substrate Working Solution by adding 6 ml Luminol/Enhancer Solution to 6
ml Stable Peroxide Solution.
10. Remove membrane from the Substrate Equilibration Buffer, carefully blotting an
edge of the membrane on a paper towel to remove excess buffer.
11. Pour the Substrate Working Solution onto the membrane so that it completely covers
the surface. Incubate membrane in the substrate solution for 5 minutes without shaking.
12. Remove membrane from the Working Solution and blot an edge of the membrane on
a paper towel for 2-5 seconds to remove excess buffer.
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13. Wrap the moist membrane in plastic wrap.
14. Place the membrane in a film cassette and expose to X-ray film for 2-5 min. Develop
the film according to manufacturer’s instructions.
Table 1
dH2O
10x Bing Buffer
1g/l Poly (dI dC)
50% Glycerol
1% NP-40
100 mM MgCl2
Super Sift Antibody
Unlabeled Target DNA
Protein Extract
Biotin End-labeled Target
DNA
Unlabeled EBNA DNA
EBNA Extract
Biotin-EBNA Control DNA

Final Amount
1X
50 ng/l
2.50%
0.05%
5 mM
5 l
4 pmol
3 g
20 fmol
4 pmol
1 Unit
20 pmol

 7. Preparation of fatty acid enriched media
a). Prepare fatty acids stock solution
1. The pure fatty acids are purchased from NuCheck.
2. Get fatty acid from the commercial container, record the weight of fatty acid (X mg),
and the molecular weight (MW). Make a 5 ml solution in graduated flask and then
calculate the final concentration:
N1 (mM) = X mg × 1000
5 ml × MW
3. Fill the graduated flask with gas N2 and seal with parafilm.
b). Prepare fatty acids enriched media
1. Calculate how much fatty acid solution in hexane we will need. Suppose the final
concentration of fatty acid in media (10 ml) is 20µM
V1N1=V2N2
X×N1 =10×0.02
X (μl) = 10×0.02
N1
2. Take a glass tube put NaOH 30 times exceed of fatty acid concentration. Volume of 6
N NaOH:
V3 = FA conc.×30× V2
6
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Put NaOH (V3) in a culture glass tube, and then add FA (V1).
Carefully blow in the gas N2 for 15 min to 30 min until it totally dried.
3. Wash out fatty acid from glass tubes into the media (V2).
Adjust pH of the media to 7.4 with HCl.
4. Filtration through the syringe filter or bottle filters (0.02 μm), then add to the cells.
 8. Superoxide measurement
1. Grow cells in microplates (24 or 48) well plates. Include a control groups to be used as
negative and positive controls.
2. Wash cells at least three times with Hanks buffer to remove serum.
3. Add HEPES containing DHE (20 μmol/L) to microplates. Use 1ml for 12 wells and 0.5
ml for 24 wells and incubate for 30 min. Blank well receives HEPES buffer without DHE
probe. Wrap plate in aluminum foil to protect from the light.
4. Wash 2 to 3 times with HEPES buffer.
5. Set plate reader excitation and emission wavelengths 490 / 605 nm.
Light sensitive reactions: protect stocks from light by wrapping in aluminum foil when
adding DHE media on cells, switch off the light in the hood.
HEPES buffer (500ml pH 7.4):
NaCl: 4.237g
KCl: 186.4mg
MgCl2: 50.8mg
D-glucose: 901.0mg
HEPES: 1.1915g
CaCl2: 110.25mg
 9. Detergent-free purification of caveolin enriched membrane fractions (Sucrose
density gradient)
1. Cells were plated in 150 mm X 25mm plate/treatment. Cells were washed with PBS
and lysed with 2 ml of ice-cold MES-buffered saline (MBS; 25mM MES
(morpholineethanesulfonic acid, pH 6.5), 150 mM NaCl) containing 500 mM Na2CO3.
25 mM MES: 2.4405 g in 500 ml water, adjust PH to 6.5.
Then add 4.383g NaCl into MES, achieve MBS.
Take 50 ml MBS, add 2.65g Na2CO3, get 500mM. This is lysis buffer.
90% Sucrose: 45g sucrose and make final volume 50 ml. Heat in water bath to dissolve.
35% Sucrose: 17.5 g sucrose and final volume 50 ml.
5% sucrose: 2.5 g sucrose and final volume 50 ml.
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2. Homogenization was carried out with 10 strokes of a loose-fitting Dounce
homogenizer. After homogenized, get samples into 15ml cornival tubes for sonication
3. After sonication, centrifuge at 3,000 rpm for 10 min at 4°C.
4. Collect supernatant into centrifuge tubes (14 x 89mm), if it’s not exactly 2 ml, add
more MBS to reach 2 ml.
5. The homogenate was adjusted to 45% sucrose by addition of 2 ml of 50ml 90%
sucrose prepared in MBS and placed at the bottom of an ultracentrifuge tube, and
overlaid with a discontinuous sucrose gradient.
Add 2 ml 90% sucrose to make the final 45% sucrose, add into tube slowly against walls,
then vortex to mix well.
6. Add 5 ml of 35% sucrose. Use 1 ml pipette five times.
7. Add 3 ml of 5% sucrose. Then the tube is pretty full.
8. Measure weight of the tubes, put the one with more volume first on the scale, set to 0.
Then put the less volume ones. Achieve 0 with 5% sucrose.
9. Get the rotor (SW 41) from 4°C. Centrifuge 39,000 rpm for 18 h.
10. The second day morning, collect fractions into 1.5ml clear tubes. Label 1 to 12, can
see a white fraction which is Cav-1 enriched faction. Sometime the 12th fraction has a
little bit less or more volume.
11. Run the gel. 15 μl sample+ 3 μl 6x loading buffer.
Run the gel for 12 fractions on each western blot gel.
 10. Small interfering RNA (siRNA)
1) To begin, siRNA concentrations must be determined.
2) Incubate the siRNA mix 5 min at RT
3) Add Gene Silencer mixture to each diluted siRNA
4) Incubate the Transfection Mix 5 min at RT
5) Wash cells 2 times with serum-free OptiMEM
6) Add serum-free OptiMEM to the Transfection Mix
7) Add 1ml of the mixture to each well
8) Add 1ml of 20% FBS OptiMEM to get final 10% FBS concentration 4 hours later
9) Treat the cells 48 hours later
 11. Measurement of bilirubin production
1) All further manipulations were carried out in a dark room.
2) After incubation, 0.5 ml of each culture supernatant was collected and 250 mg BaCl2.
2H2O was added.
3) After vortexing, 0.75 ml benzene was added; then, tubes were vortexed vigorously
leading to the formation of a relatively stable milky-white emulsion.
4) After centrifugation, the upper benzene layer was collected and the absorbance was
measured at 450 nm with a reference wavelength at 600 nm using a SpectraMaxPro M2
spectrophotometer (Molecular Devices, Sunnyvale, CA).
5) In a separate tube, 0.5 ml of fresh culture medium was processed in the same way and
the benzene layer was collected and used as a blank.
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6) The quantity of bilirubin produced was calculated using a molar extinction coefficient
of bilirubin dissolved in benzene, with the molar extinction coefficient being e450
=27.3mM-1cm-1.
 12. MCP-1 determination by ELISA
a) Cells were seeded in 24 or 48 well microplates and grown to confluence.
b) After treatment, supernatants of cell cultures were collected into microcentrifuge tubes
(Isc BioExpress, UT), centrifuged at 4 °C to remove cellular debris and then stored at 80 °C.
c) MCP-1 levels were assessed using a MCP-1-specific enzyme immunoassay [190] (BD
Biosciences, CA) following the manufacturer’s protocol (adapted from BD web site,
Cat. No. 559017):
1. Add 100 μl standard or sample to each well.
Incubate 2 hours at room temperature.
2. Aspirate and wash 5 times.
3. Add 100 μl prepared Working Detector to each well.
Incubate 1 hour at room temperature.
4. Aspirate and wash/soak 7 times.
5. Add 100 μl Substrate Solution to each well.
Incubate 30 minutes at room temperature.
6. Add 50 μl Stop Solution to each well.
7. A microplate spectrophotometer SpectraMaxPro M2 (Molecular Devices Corporation,
CA) was used to read the plate at 450 nm. λ correction 570 nm.
 13. Transfection of antisense oligodeoxynucleotides into porcine endothelial cells
1) The sequences of the phosphorothioate double-stranded antisense
oligodeoxynucleotides (ODNs) against the AP-1 binding site used in this study was AP-1
decoy ODN, 5’-AGCTTGTGAGTCAGAAGCT-3’and AP-1 mismatched ODN, 5’AGCTTGAATCTCAGAAGCT-3’.
2) The double-stranded ODNs were prepared from complementary single-stranded
phosphorothiolate-bonded oligonucleotides.
3) The ODNs were annealed for 1 h, while the temperature descended from 80 to 25 °C.
4) DNA derived from endothelial cells was precomplexed with the PLUS reagents (Life
Technologies, Rockville, MD) at room temperature for 15 min.
5) The pre-complexed DNA was combined with diluted LipofectAMINE reagent (Life
Technologies), mixed and incubated for 15 min at room temperature.
6) While complexes were forming, medium with serum-free transfection medium were
replaced.
7) Then DNAPLUS Lipofect AMINE reagent complex was added to each well
containing fresh medium, and cells were incubated for 5 h.
8) After incubation, complete medium with serum was added.
9) After transfection for 48 h, cell extracts were prepared for Real-time PCR analysis.
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 14. Extraction of EGCG from cultured cells for LC/MS/MS analysis
1) After removing the media, cells were washed in cold PBS twice.
2) Cells were scraped in 2 ml cold PBS containing 100 l 20% ascorbic acid solution and
50 pmol internal standards (ethyl gallate).
3) Add cell suspension or aqueous samples up to 2ml volume to 4 ml Ethyl Acetate in 8
ml glass tube.
4) After 10 min vortex mixing, cells were centrifuged at 3000 rpm, 10 min, 25°C.
5) Remove upper organic phase to 4ml vial, evaporate to dryness under a gentle N2
stream in a water bath.
 15. Quantification of EGCG by LC/MS/MS analysis
1) After drying the extracts under nitrogen, they were reconstituted with 50: 50 water:
acetonitrile and injected into LC/MS/MS.
2) LC/MS/MS analyses of polyphenols were performed using an ABI 4000-Qtrap hybrid
linear ion trap triple quadrupole mass spectrometer in multiple reaction monitoring
(MRM) mode.
3) Polyphenols were separated using an Eclipse XDB C8, 5 µM, 4.6 X 150 mm (Agilent)
column.
4) The mobile phase consisted of water with 0.1% formic acid as solvent A and
acetonitrile with 0.1 % formic acid as solvent B.
5) For the analysis of polyphenols the separation was achieved by starting with 0%
solvent B, which was gradually increased to 100% over 10 min, and maintained it at 100%
for the last 2 min.
6) The column was equilibrated to initial conditions in 3 min.
7) The flow rate was 0.5 ml/min with a column temperature of 30 °C.
8) The sample injection volume was 10 µl.
9) The mass spectrometer was operated in the negative electrospray ionization mode with
optimal ion source settings determined by synthetic standards of EGCG with a
declustering potential of -40 V, entrance potential of -10 V, collision energy of -18 V,
collision cell exit potential of -17 V, curtain gas of 20 psi, ion spray voltage of -4500 V,
ion source gas1/ gas2 of 40 psi and temperature of 550 °C.
10) MRM transitions monitored were as follows: 457.1/168.9 and 457.1/124.9 for EGCG;
197.1/168.6 and 197.1/124.6 for ethyl gallate.
11) LC/MS/MS calibrations were obtained with R2 values ≥ 0.998.
 16. Cignal Reporter Assay (Transfection for Dual-Luciferase Reporter Assay)
1) Prepare nucleic acid mixtures in appropriate ratios.
Experimental transfection (Cignal Reporter+ test nucleic acid);
Control transfection ( a. Cignal Reporter+ negative control for test nucleic acid; b. Cignal
Negative Control+test nucleic acid; c. Cignal Negative Control+negative control for text
nucleic acid; d. Cignal Positive Control)
2) Dilute Sure FECT into Opti-MEM
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3) Add diluted SureFECT to nucleic acid mixture, incubate at room temperature for 20
min
4) Trypsinize, count and suspend cells to appropriate density
5) Aliquot transfection complexes into wells, immediately seed cells to each well
6) Incubate 37°C for 16 h.
7) Change media to assay media (0.5% FBS)
 17. Dual-Luciferase Reporter Assay
1) Prepare 1X PLB (passive lysis buffer, dilute 5X PLB), LAR II (Luciferase Assay
reagent II), and Stop & Glo Reagent (mix 50X Substrate and Stop & Glo Buffer). Thaw
the reagent and buffer at room temperature.
2) Remove the medium from the culture dishes and wash twice with PBS. Completely
remove PBS before applying PLB.
3) Dispense into each culture well the following volume of 1X PLB.
6 well plate
12 well plate
24 well plate
96 well plate

500ul
250ul
100ul
20ul

4) Place the culture plates on a rocking platform at room temperature for 15 minutes.
Meanwhile, place LAR II and Stop & Glo Reagent at room temperature.
5) Transfer the lysate to a tube or directly add 20µl to a well of 96 well luciferase activity
measuring plate.
6) Dispense 20µl of lysate into luminometer plate.
7) Turn on the luminometer and prime both injectors with LAR II and Stop & Glo
Reagent.
8) Program it to perform 2-second premeasurement delay, followed by a 10-second
measurement period for each reporter assay.
9) Begin measurement.
10) Wash the injectors once with water and once with air.
11) Store the remaining reagent at -70C up to 1 month.
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